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Clinical features and treatment 
Synovial sarcoma (SS) is an aggressive malignancy with few specific 
therapies (Haldar et al., 2008). It is a rare disease, comprising between 7 and 10 
percent of all sarcoma cases and is diagnosed primarily in adolescents and 
young adults. Tumors are typically found near the joints but can arise in many 
locations throughout the body (Ladanyi, 2001; dos Santos et al., 2001). SS 
displays a high degree of metastasis, particularly to the lungs as well as the bone 
marrow and lymph nodes (dos Santos et al., 2001). The primary treatment 
involves tumor resection and may include the addition of radiation or 
chemotherapy (Haldar et al., 2008). Even with these interventions, the survival 
rates of SS remain low and can range from 25-60% 5-year survival and a 10-year 
survival between 10 and 30% (Ladanyi, 2001; dos Santos et al., 2001). 
In spite of its name, synovial sarcoma is not actually derived from synovial 
tissue and is believed to arise from the transformation of some type of stem cell 
with the capacity to differentiate into epithelial and mesenchymal lineages (dos 
Santos et al., 2001). This is based on tumor histology which also allows for the 
classification of SS into three clinical subtypes: monophasic, biphasic, and poorly 
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differentiated. Monophasic tumors have spindle shaped cells that are small with 
little cytoplasm (Haldar et al., 2008). Biphasic tumors have compartments 
displaying glandular structures in addition to the spindle cell compartment, and 
the cells in poorly differentiated tumors have a morphology intermediate between 
the spindle and epithelial cells. Interestingly, all subtypes of SS display markers 
of epithelial differentiation making them unique among sarcomas. Another 
feature of SS is the presence of a recurrent chromosomal translocation 
t(X;18)(p11.2;q11.2) which can be detected in over 90% of all SS tumors (dos 
Santos et al., 2001). This genetic abnormality provides a characteristic feature 
which can be exploited to understand the molecular biology of synovial sarcoma 
tumors and lead to the development of more specific therapies in the future. 
 
Molecular features of synovial sarcoma 
 Because of its specific association with SS as well as its presence in all 
compartments of the tumor and persistence throughout tumor growth, the 
product of the t(X;18) translocation is thought to drive SS tumor formation (dos 
Santos et al., 2001; Ladanyi, 2001). This mutation results in the aberrant fusion 
of the SYT gene (for “synovial sarcoma translocation,” also known as SS18) on 
chromosome 18 with one of the SSX (“synovial sarcoma X chromosome 
breakpoint”) family members located on the X chromosome (Clark et al., 1994; 
Crew et al., 1995; Skytting et al., 1999). The fusion gene is transcribed and 
encodes a functional protein in which the C-terminal 78 amino acids of SSX 
replace the last 8 amino acids of SYT (Figure 1; Clark et al., 1994). Most 
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translocations involve the same breakpoints in SYT and either SSX1 or SSX2, 
but variations in the fusion are seen involving different breakpoints and alternate 
family members like SYT-like (SYTL) and SSX4 (Crew et al., 1995; Skytting et 
al., 1999; Brodin et al, 2001; Storlazzi et al., 2003). SYT-SSX proteins localize in 
the nucleus where they may dictate tumorigenesis through the modulation of 
gene transcription (Thaete et al., 1999; Brett et al., 1997; dos Santos et al.,1999). 
 Both wild-type SYT and SSX proteins are nuclear co-regulators of 
transcription, and the subversion of their normal activities could contribute to 
cellular transformation. SYT is a ubiquitously expressed protein that is essential 
for development. Knock-out animals display embryonic lethality due to placental 
and cardiac defects (de Bruijn et al., 1996; de Bruijn et al., 2006b; Kimura et al., 
2009). SYT resides predominantly in the nucleus where it displays a distinct 
speckled pattern (Thaete et al., 1999; Brett et al., 1997; dos Santos et al., 1999). 
It colocalizes with Brg1 and Brm in these nuclear foci, and this association is 
dependent on the N-terminus of SYT (Thaete et al., 1999; Ishida et al., 2004). 
This interacting region is evolutionarily conserved and is called the SYT N-
terminal Homology (SNH) domain (Thaete et al., 1999). The SNH domain also 
mediates interactions with other proteins including the transcription factor AF10 
and the histone modifiers p300 and mSin3a (Figure 1; de Bruijn et al., 2001; Eid 
et al., 2000; Ito et al., 2004). SYT contains an additional function domain at its C-
terminus that has transactivation activity. It is referred to as the QPGY domain 
because of the abundance of glutamine, proline, glycine, and tyrosine residues 
(Figure 1; Thaete et al., 1999; Brett et al., 1997). This bears similarity to the 
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activation domain found in EWS/FUS/TLS proteins and is a domain that is also 
seen in the p250 and p250R proteins that are components of the mammalian 
SWI/SNF (mSWI/SNF) complex (Thaete et al., 1999; Kato et al., 2002). 
Interaction with the nuclear receptor Co-activator Activator (CoAA) protein occurs 
through the QPGY domain, and SYT may homo-dimerize through this  
module as well (Iwasaki et al., 2005; Perani et al., 2005; Perani et al., 2003). 
Notably, SYT lacks a DNA binding domain (Clark et al., 1994), and together 
these data indicate that SYT may mediate its function through protein-protein 
interactions that regulate transcription. 
 Early studies on the function of SYT reveal a role in transcriptional 
activation; however, the mechanism of its activity is still not understood. Previous 
work indicates that SYT plays a role in general transcription, and fusion of SYT to 
the Gal4 DNA binding domain results in reporter gene activation (Iwasaki et al., 
2005; Ishida et al., 2004). This can be enhanced by deletion of the N-terminus 
and may be due to the association of mSin3a with the SNH domain (Ishida et al., 
2004; Ito et al. 2004). Some evidence suggests that negative regulation of SYT 
activity also occurs through its interaction with Brg1/Brm; however, this is not 
corroborated by other reports (Ishida et al., 2004; Iwasaki et al., 2005). In 
addition, SYT can activate hormone-responsive promoters in a ligand-dependent 
manner with its binding partner, CoAA, requiring either Brm or Brg1 and the 
QPGY domain (Perani et al., 2005; Iwasaki et al., 2005). In summary, SYT 
involvement in transcriptional activation requires its interaction with other proteins 




 Downstream of transcription, SYT appears to play a role in the regulation 
of adhesion. Association with p300 occurs specifically in the context of adherent 
cells (Eid et al., 2000). Moreover, adhesion to fibronectin is inhibited in the 
presence of a C-terminal mutant of SYT lacking the last 8 amino acids 
(mimicking the portion of the protein involved in the SYT-SSX translocation) (Eid 
et al., 2000). Additional studies have revealed a role for SYT in the formation of 
epithelial cysts in 3D culture as well as migration, further highlighting the 
importance of SYT in adhesion (Chittezhath et al., 2008; Kimura et al., 2009). 
Overall, SYT mediates transcriptional activation through interactions with multiple 
proteins and may integrate signals from a variety of pathways including 
hormones and extracellular matrix adhesion. 
 In contrast, the SSX genes encode transcriptional co-repressors whose 
physiological function remains unclear. These proteins are typically 188 amino 
acids in length, and their genes are found in 2 clusters on the X chromosome that 
are approximately 3Mb away from one another (Güre et al., 2002). There are 9 
family members in all, and they are characterized by the presence of 2 domains 
involved in transcriptional repression: an N-terminal Krüppel-associated box 
(KRAB) domain and a C-terminal SSX Repressor Domain (SSXRD) (Figure 1; 
Crew et al., 1995; Lim et al., 1998). The primary functional domain of SSX 
proteins is the SSXRD, a region that is highly conserved among all family 
members (Güre et al., 2002). This domain is responsible for SSX nuclear 
localization as well as the bulk of its repressor activity (dos Santos et al., 2000; 
Thaete et al., 1999). The KRAB domain is found in a large sub-family of 
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transcriptional repressors, but in SSX proteins, it appears to play a 
supplementary role by augmenting repression mediated by the SSXRD (Crew et 
al., 1995; Lim et al., 1998; Thaete et al., 1999). Notably, like SYT, SSX proteins 
lack a DNA binding domain; therefore, they may also exert their function via 
protein-protein interactions (Crew et al., 1995). 
 Very few interacting partners of SSX proteins have been identified to date. 
Early studies reveal nuclear localization of SSX1 and SSX2, and it was later 
determined that SSX2 associated with Polycomb proteins (Brett et al., 1997; dos 
Santos et al., 1999; dos Santos et al., 2000). The Polycomb proteins are 
important regulators of differentiation and development that maintain silencing of 
lineage-specific genes through the modulation of chromatin structure (see 
below). The interaction between Polycomb proteins and SSX is dependent on the 
SSXRD, further highlighting the functional importance of this domain (dos Santos 
et al., 2000). In addition, SSX can co-precipitate histone oligomers and oligo-
nucleosomes suggesting that SSX proteins may also be targeted through direct 
interactions with chromatin (Kim et al., 2009). Nevertheless, SSX1 binds to the 
transcription factor LHX4, and this association leads to the decreased expression 
of an LHX4-responsive reporter gene (de Bruijn et al., 2008). Other studies have 
identified additional interacting proteins; however, the functional consequences of 
SSX binding with these partners has not been elucidated (de Bruijn et al., 2002). 
 SSX proteins are also of general interest because of their potential role in 
many different cancers. The SSX family belongs to a class of proteins known as 
cancer-testis (CT) antigens because of their normal tissue distribution and 
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expression in malignancies (Smith and McNeel, 2010). CT antigens are nearly 
exclusively expressed in the testis; however, their aberrant expression in a 
variety of tumors derived from multiple tissues can produce an immune response 
in patients. This opens the possibility of using SSX peptides in vaccines for tumor 
immunotherapy for several cancers in addition to synovial sarcoma (Smith and 
McNeel, 2010). Thus, SSX as well as SYT are important proteins outside of their 
association with SS, and understanding their wild-type functions will expand our 
knowledge of both development and cancer.  
 
Cellular Reprogramming and Cancer 
 
 Recently, it has been hypothesized that tumors are maintained by a small 
population of cancer stem cells (CSCs) that, when isolated, are able to 
repopulate the entire tumor with all of its various phenotypes (Lobo et al., 2006). 
The mechanism of how CSCs arise is not known; however, there are parallels 
between tumorigenesis and the process of cellular reprogramming by which 
normal, terminally differentiated somatic cells can be induced to behave like 
pluripotent stem cells (Abollo-Jiménez et al., 2010; Castellanos et al., 2010). 
Both require the gain of stem cell characteristics as well as the active repression 
of a cell‟s endogenous differentiation program (Lobo et al., 2006; Gurdon and 
Melton, 2008; Abollo-Jiménez et al., 2010). These alterations, in turn, depend on 
changes in gene transcription through the action of lineage-specific transcription 
factors, epigenetic regulators, and signaling molecules (Abollo-Jiménez et al., 
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2010; Castellanos et al., 2010). SYT-SSX expression is associated with the 
activation of multiple signaling pathways, and it can interact with a number of 
proteins that control transcription through genetic and epigenetic mechanisms. 
These data suggest that SYT-SSX mediates transformation through aberrant 
cellular reprogramming. 
 
Activation of signaling pathways by SYT-SSX 
 Many molecules involved in extracellular signaling pathways are activated 
in SS tumors and cell lines. A number of studies have reported the upregulation 
of various receptor tyrosine kinase pathway components including Igf2, HGF and 
c-Met, ephrin ligands and Eph receptors, FGF ligands and receptors, EGFR, and 
PDGFR (de Bruijn et al., 2006a; Watanabe et al., 2006; Barco et al., 2007; Ishibe 
et al., 2005; Bozzi et al., 2008). Several of these pathways converge on MAPK 
signaling leading to changes in cell proliferation, migration, and anchorage-
independent growth and thus contribute to cellular transformation (Fukukawa et 
al., 2009; Watanabe et al., 2009; Watanabe et al., 2006). Moreover, the 
expression of ligands and their cognate receptors, as in the case of HGF and c-
Met, ephrin and Eph receptors, and FGF signaling molecules, indicates that SYT-
SSX mediates the formation of autocrine signaling loops. This may help to 
establish and maintain the transformed program in SS. 
 The non-canonical Wnt pathway is also active in some SS cell lines 
(Fukukawa et al., 2009). Signaling through this pathway affects anchorage-
independent growth through Rac1 and JNK activation (Fukukawa et al., 2009). 
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Similarly, in the absence of canonical signaling events, -catenin localizes in the 
nucleus and forms a complex with SYT-SSX2. This complex can activate a 
reporter gene, but the endogenous targets of this complex are not known (Pretto 
et al., 2006). This is evidence that not only does SYT-SSX activate different 
signaling pathways that contribute to the transformed phenotype, but it also has 
the capacity to change transcriptional programs directly. 
 
Transcriptional deregulation by SYT-SSX 
Based on their wild-type activities, the fusion of SYT to SSX generates a 
protein with an enigmatic function as it has the potential to mediate opposing 
behaviors. In the translocation, the SNH and QPGY domains of SYT are retained 
and fused to the C-terminal end of SSX with the SSXRD remaining intact (Figure 
1, Pretto et al., 2006). Because these domains mediate protein-protein 
interactions with activators and repressors of transcription, it can be conjectured 
that SYT-SSX functions through both aberrant silencing and activation of target 
genes that contribute to tumorigenesis. 
 One mechanism by which SYT-SSX may induce and maintain tumor 
formation is through downregulation of tumor suppressor genes. SYT-SSX1 was 
shown to associate with wild-type SYT, and both proteins are bound to the 
COM1 tumor suppressor promoter region (Ishida et al., 2007). Expression of 
SYT-SSX1 led to the downregulation of COM1 which could be abrogated by 
exogenous expression of wild-type SYT. This suggests that SYT-SSX acts in a 
dominant negative manner to inhibit the normal function of SYT (Ishida et al., 
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2007). Similarly, SYT-SSX2 directly repressed the activity of EGR1, a putative 
tumor suppressor and SYT target gene (Lubieniecka et al., 2008). Wild-type SYT 
and SYT-SSX2 associate with the EGR1 promoter; however, SYT-SSX2 
uniquely recruits Polycomb proteins to this locus. Altogether, these studies 
indicate that silencing of SYT target genes is one method of transcriptional 
deregulation mediated by SYT-SSX. 
 The activation of gene transcription by the fusion protein also contributes 
to tumor formation. As mentioned above, the IGF pathway is implicated in SS 
formation by a number of studies and correlates with increased cell proliferation 
and metastasis (Xie et al., 1999; Allander et al., 2002; de Bruijn et al., 2006a; 
Sun et al., 2006; Törnkvist et al., 2008). Furthermore, IGF2 neutralizing 
antibodies are able to increase apoptosis in SS cell lines (Sun et al., 2006). SYT-
SSX proteins may directly affect expression of the IGF2 gene through 
deregulation of its imprinting (de Bruijn et al., 2006a; Sun et al., 2006; Cironi et 
al., 2009). The exact mechanism of how this occurs is unclear, but altered 
methylation of the imprinting control region appears to play a role in this process 
(Sun et al., 2006; Cironi et al., 2009).  
 We have already discussed how Polycomb proteins may be aberrantly 
targeted to SYT target genes, and previous work in our lab reveals that the 
reverse may also occur. SYT-SSX2 expression in U2OS human osteosarcoma 
cells leads to a reduction in total protein levels of Bmi1 through enhanced 
degradation (Barco et al., 2009). This results in reduced association between 
Bmi1 and its functional partner, Ring1b, a global decrease in histone H2A 
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ubiquitylation, the enzymatic activity catalyzed by Ring1b and facilitated by Bmi1, 
and the increased expression of Polycomb target genes (Barco et al., 2009). 
Together, these data demonstrate that SYT-SSX alters the gene expression 
profile of the cell by epigenetic mechanisms. 
 Additionally, SYT-SSX interacts with sequence-specific transcription 
factors to mediate transcriptional activation.  SYT-SSX induces the expression of 
E-cadherin. E-cadherin protein is found in biphasic SS which displays glandular 
differentiation of its epithelioid compartment. Both SYT-SSX1 and SYT-SSX2 
activate the E-cadherin promoter through interaction with the repressors Snail 
and Slug (Saito et al., 2006). SYT-SSX also binds to LHX4 resulting in the 
activation of an LHX4 reporter gene (de Bruijn et al., 2008). LHX4 is involved in 
pituitary development and is linked to human disorders related to aberrant 
pituitary function (Machinis et al., 2001). Thus SYT-SSX can mediate 
transcriptional activation through association with lineage-specific transcription 
factors. In summary, the studies described above indicate that SYT-SSX 
regulates transcription via both genetic and epigenetic means.  
 
Tumorigenesis depends on cell-intrinsic and extrinsic factors 
  The process of reprogramming is inefficient and depends on the level of 
differentiation in the original cell (Gurdon and Melton, 2008) suggesting that 
tumor formation by this mechanism will display similar characteristics. The 
potential of SYT-SSX to cause widespread transcriptional deregulation implies 
that its expression will always result in transformation; however, this is not the 
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case. SYT-SSX1 induces anchorage-independent growth and tumor formation in 
nude mice when expressed in rat 3Y1 fibroblasts (Nagai et al., 2001), yet 
additional reports on SYT-SSX-mediated transformation provide conflicting 
results. Human MSCs expressing SYT-SSX1 are unable to form tumors in 
immune deficient mice (Cironi et al., 2009), and previous work in our lab reveals 
that SYT-SSX2 is unable to transform NIH3T3 fibroblasts in vitro (Barco et al., 
2007). This may be due to the ability of SYT-SSX to activate expression of p21, a 
direct target of the fusion in some cell types, including NIH3T3 cells (Tsuda et al., 
2005). Interestingly, it is postulated that tumor suppressor pathways function as 
barriers to reprogramming (Abollo-Jiménez et al., 2010; Castellanos et al., 2010). 
Taken together, these data suggest that transformation by SYT-SSX proteins 
only occurs under conditions (intrinsic and extrinsic to the cell) that are 
permissive for reprogramming. 
 In vivo experiments indicate that tumorigenesis also relies on the cell 
differentiation status and the surrounding microenvironment. Mouse modeling of 
SS revealed that SYT-SSX2 alone could drive tumorigenesis, however, its effect 
was limited to transgenic animals in which the oncogene was expressed in Myf5-
positive myoblasts (Haldar et al., 2007). Induction of SYT-SSX2 in less 
differentiated myogenic progenitor populations or in more differentiated myocytes 
did not result in tumor formation. Moreover, even in Myf5-positive cells, SYT-
SSX2 caused apoptosis in vivo except in populations growing adjacent to the 
future cartilage of the rib. Thus, the target cell must meet certain requirements of 
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cell fate commitment and location in order to become transformed by SYT-SSX 
(Haldar et al., 2007; Haldar et al., 2009). 
Overall, it appears that the fusion protein functions through the recruitment 
of regulators that can override the normal transcriptional status at a given locus. 
Moreover, contributions from both components of the fusion protein are required 
for its molecular activity; therefore, transformation by SYT-SSX depends on its 
ability to alter gene expression. This causes the activation of multiple signaling 
pathways, silencing of tumor suppressors, and the expression of other genes 
resulting in the acquisition of SS-associated phenotypes. In addition, the nature 
of the initiating cell is also important, and its properties can determine whether 
tumors form. These attributes parallel features of cellular reprogramming and 
leads to the hypothesis that SYT-SSX directs tumorigenesis by this process. 
Elucidating the characteristics of the aberrant program initiated by SYT-SSX, 
therefore, is essential to understanding the biology of SS. 
 
Epigenetic Regulation of Development 
 
Epigenetics refer to inherited changes in gene expression that occur 
independently of alterations in the DNA primary structure (Jones and Baylin, 
2007). Stem cells employ epigenetic mechanisms to control the expression of 
developmental regulators either to maintain multipotency or to carry out cellular 
differentiation. Modulation of chromatin structure is one aspect of epigenetic 
regulation and is mediated by the action of many proteins the best characterized 
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being the Polycomb group (PcG) proteins and the SWI/SNF complex (Lessard 
and Crabtree, 2010). 
PcG proteins are an evolutionarily conserved family of proteins that make 
up 2 classes of complexes in mammals: Polycomb Repressive Complex 1 
(PRC1) and PRC2 (Kerppola, 2009; Schuettengruber et al., 2007). Each complex 
has a unique set of core components, some with multiple homologs, as well as 
associated activities that characterize it (Kerppola, 2009). The core PRC1 
proteins are Bmi1, Cbx, Phc, and Ring1, which catalyzes the ubiquitylation of 
histone H2A on lysine 119 (H2AUb) (Kerppola, 2009; Schuettengruber et al., 
2007). In addition, PRC1 can associate with methylated histone tails via the 
chromodomain of Cbx proteins (Kerppola, 2009). Through the activity of the Ezh1 
and Ezh2 proteins, PRC2 is able to trimethylate histone H3 on lysine 27 
(H3K27me3) (Schuettengruber et al., 2007). The other core proteins of PRC2 are 
Eed and Suz12 and are required for the methyltransferase activity of the Ezh 
proteins (Kerppola, 2009; Simon and Kingston, 2009; Schuettengruber et al., 
2007). Additional factors may associate with both PRCs increasing the variability 
of these complexes, and the function of PRC1 and PRC2 may be modulated by 
the presence of these proteins (Kerppola, 2009; Simon and Kingston, 2009).  
PcG proteins were discovered in Drosophila through mutations resulting in 
aberrant development (Simon and Kingston, 2009; Schuettengruber et al., 2007). 
It has since been determined that Polycomb proteins function in stem cells to 
prevent inappropriate differentiation through the repression of target genes 
(Kerppola, 2009). Indeed, many targets of Polycomb are lineage-specific and 
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become activated during development (Lessard and Crabtree, 2010). The 
mechanisms of how Polycomb complexes mediate gene silencing are not well-
understood, however, it may occur through chromatin compaction, cooperation 
with DNA methylation, or blockade of transcriptional elongation (Kerppola, 2009; 
Simon and Kingston, 2009; Schuettengruber et al., 2007).  
The activity of Polycomb complexes is antagonized by another class of 
proteins known as the Trithorax group (TrxG) (Schuettengruber et al., 2007). 
TrxG proteins also function in complexes that fall into 2 categories: histone 
methyltransferases and nucleosome remodelers (Schuettengruber et al., 2007). 
The mammalian SWI/SNF complex (SWI/SNF, also known as the BAF complex) 
is an ATP-dependent chromatin remodeler comprised of 12 proteins and 
homologous to a yeast complex bearing the same name (Lessard and Crabtree, 
2010). Like Polycomb complexes, SWI/SNF complexes containing alternate 
components mediate different functions. For example, Brg1 is required for 
embryonic development and mediates the activation of the zygotic genome while 
Brm does not appear to be essential for this process (Lessard and Crabtree, 
2010). The mechanism of how SWI/SNF complexes abrogate Polycomb 
silencing is not clear; however, it may involve the decompaction of chromatin as 
well as the activity of other TrxG members. 
 The PcG and TrxG proteins function to maintain the expression status of 
genes when the initiating signal for either repression or activation is gone 
(Kerppola, 2009). This indicates that these proteins are responsible for the 
persistence of a particular program that was established by another factor. 
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Interestingly, SYT-SSX proteins interact with both PcG proteins and the 
SWI/SNF ATPases (Thaete et al., 1999; Nagai et al., 2001; dos Santos et al., 
2000; Barco et al., 2009). The capacity to bring together these opposing 
functions implies not only the deregulation of the targets of these complexes but 
also the persistence of the altered program in the resulting tumor. 
 SYT-SSX directly mediates both transcriptional activation and repression 
through regulating the activity of PcG complexes (Lubieniecka et al., 2008; Barco 
et al., 2009). These data provide a mechanistic basis for epigenetic changes that 
may result in cellular reprogramming. Controlling transcription is central to 
tumorigenesis by SYT-SSX, thus further defining how the fusion accomplishes 
alterations in gene expression is essential to the development of specific 
therapies for the treatment of SS. 
 
Purpose of this study 
  
 Players that are central to the maintenance of nuclear programs interact 
with SYT-SSX proteins. This enables SYT-SSX to dictate its own agenda within a 
target cell and propagate that program to daughter cells. Investigating the nature 
of the oncogenic program of SYT-SSX is necessary for the generation of more 
effective therapeutic interventions. The goal of this study is to define that 
program and the mechanism by which it is established. 
 Chapter 3 discusses the nature of the program activated by SYT-SSX2 in 
mesenchymal stem and progenitor cells. SS is a tumor believed to be derived 
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from mesenchymal tissues, and previous studies have suggested that it 
originates in stem cells. Upon its expression, SYT-SSX2 induces the expression 
of developmental and tissue-specific differentiation regulators. Moreover, a 
predominant activation of genes involved in neural lineages (neuronal and glial) 
occurs. This is associated with the formation of long projections and the 
expression of neurofilament protein. Genome-wide binding studies on SYT-SSX2 
reveal that it is targeted to many of the neural-associated genes indicating their 
direct regulation by the fusion protein. In addition, SYT-SSX2 is recruited to the 
Fgfr2 gene, and its association with Fgfr2 correlates with expression. FGF 
signaling mediates the neural phenotype displayed by SYT-SSX2-expressing 
cells, and the inhibition of this signaling pathway results in decreased 
neurofilament expression in hMSCs transduced with the oncogene and SS tumor 
cell lines. 
 In Chapter 4, the genome-wide binding of SYT-SSX2 is studied in more 
depth in order to identify potential mechanisms of recruitment to target loci. SS 
likely originates from more than 1 progenitor cell population, and because it 
interacts with epigenetic regulators, its exact targets may differ depending on the 
initiating cell; however, the mode by which it is recruited will be similar across cell 
types. SYT-SSX2 association with the genome is non-random, and it localizes to 
distinct regions. Comparison with publicly available datasets defining regions 
enriched in specific histone modifications reveals a predominant association with 
H3K27me3, the modification characteristic of Polycomb-silenced genes. In fact, 
SYT-SSX2 occupies H3K27me3-labeled regions within or near over 70% of 
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positively-regulated and 40% of negatively-regulated genes in oncogene-
expressing cells. These data support a role for SYT-SSX2 in the re-activation of 
Polycomb-silenced genes and suggest that Polycomb complexes serve as a 
recruitment module for the fusion protein. An additional subset of downregulated 
SYT-SSX2 target genes are characterized by association of the protein with 
histone modifications that correlate with transcriptional activation. Taken 
together, there are at least 2 mechanisms of SYT-SSX2 recruitment to target 
genes, one dependent on PcG proteins, and the other Polycomb-independent. 
 Chapter 5 covers the molecular mechanism of SYT-SSX2-mediated 
Polycomb derepression. Previous work shows that SYT-SSX2 abrogates 
silencing by PRC1 resulting in transcriptional activation due to enhanced 
degradation by Bmi1. A variety of cellular stresses in myoblasts, including SYT-
SSX2 expression, results in alterations of Bmi1 mobility by SDS-PAGE. This is 
due to increased phosphorylation. SYT-SSX2 expression also leads to the loss of 
Bmi1 from a PRC1 target gene, Ngfr. This change was accompanied by 
alterations in histone modifications (from silent to active) and expression of Ngfr 
transcripts. Ngfr expression depends on the presence of the N-terminus of SYT, 
known to interact with Brg1 and p300. Studies with purified PRC1 components 
Ring1b and Bmi1 reveal that the ubiquitin E3-ligase activity of Ring1b is inhibited 
in the presence of SYT-SSX2-purified complexes. These data provide the 
foundation for additional mechanistic studies and indicate that SYT-SSX2 
deregulates PRC1 function by inhibition of Ring1b activity. This may occur 
directly or by the recruitment of deubiquitylase activity. In summary, these data 
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MATERIALS AND METHODS 
 
Molecular and cellular biology 
 
Cell culture 
U2OS human osteosarcoma cells, C2C12 mouse myoblasts (ATCC), and HeLa 
cells were maintained in DMEM supplemented with 10% FBS. The human 
synovial sarcoma SYO-1 cells (Kawai et al., 2004) were provided by T. Ito and M. 
Ladanyi and grown in collagen-coated (20 µg/ml) dishes with DMEM and 10% 
FBS. Human multipotent bone marrow mesenchymal stem cells (hMSCs) were 
acquired from Darwin Prockop‟s laboratory at the Texas A&M Health Science 
Center College of Medicine (TAMHSCCOM) Institute for Regenerative Medicine 
at Scott and White Hospital and maintained in their recommended growth 
medium. These were used in the experiments described throughout Chapter 3 
and Appendix B Figure B3 and were early passage. They were isolated 
according to protocols established by the Prockop group (Colter et al., 2001; 
Sekiya et al., 2002) for the identification of multipotent MSCs. The hMSCs shown 
in Appendix B Figure B4 were provided by P. Young and M. Alfaro (Vanderbilt 




Antibodies and reagents 
Mouse anti-Flag antibody, (Sigma, St. Louis, MO), mouse anti-H3K27me3, 
mouse anti-H3K4me3, mouse control IgG MOPC-173, (Abcam, Cambridge, MA), 
mouse anti-H3K18Ac (Cell Signaling, Danvers, MA), mouse anti-Ring1b (MBL, 
Woburn, MA), mouse anti-Bmi1, mouse anti H3K14Ac, mouse anti- H2AUb 
(Millipore, Billerica, MA), were used in chromatin immunoprecipitation (ChIP) 
assays and Western blotting. Rabbit polyclonal anti-HA (Sigma), mouse anti-NEF 
(light, medium, and heavy neurofilaments; Abcam), mouse anti-alpha-tubulin 
(Sigma), rabbit anti-FGFR2 (N-Term, Abgent, San Diego, CA), rabbit polyclonal 
anti-SSX2 B56 (Pretto et al., 2006), and mouse monoclonal anti-SYT SV11 
(Pretto et al., 2006) antibodies were used for immunofluorescence staining and 
Western blotting. Mouse anti-Glu-Glu (2PY, Covance, Princeton, NJ) and mouse 
monoclonal anti-HA 12CA5 were used for immunoprecipitation (IP) and Western 
blotting. Rabbit anti-Brg1 (Millipore) was used for Western blotting. PD173074 
was purchased from Cayman Chemical Company (Ann Arbor, MI). MG132 was 
obtained from Calbiochem (San Diego, CA). Sodium orthovanadate was 
obtained from Sigma.  
 
Retroviral Infection of C2C12 cells 
The double-tagged pOZ-HA-Flag parental vector and pOZ-SYT-SSX2-HA-Flag, 
and retroviral production and infection were described previously (Pretto et al., 
2006). The LZRS-2PY-Bmi1 vector was provided by M. van Lohuizen. 
Construction of the SXdel3 mutant was described in Barco et al., 2009. 
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mRNA Isolation and Microarray 
C2C12 myoblasts infected with retroviral pOZ vector and pOZ-SYT-SSX2 with 
greater than 90% efficiency were used as source of RNA. Human MSCs 
expressing pOZ and pOZ-SYT-SSX2 were selected as described (Nakatani and 
Ogryzko, 2003), prior to RNA isolation. Total cellular RNA was isolated 2 days 
and 4 days post-infection from SYT-SSX2- or control vector-expressing C2C12 
and hMSCs cells, respectively, using the RNeasy Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer‟s protocol.  RNA obtained from 2 independent 
experiments with each cell line was submitted to the Vanderbilt Functional 
Genomics Shared Resource. cDNA was produced from RNA samples using the 
Ambion WT Expression Kit (Applied Biosystems, Foster, CA) then fragmented 
and labeled according to the WT Terminal Labeling and Hybridization protocol 
(Affymetrix, Santa Clara, CA) prior to hybridization to the Affymetrix Mouse 
(C2C12) or Human (MSCs) Gene 1.0 ST array. Signal intensities were 
normalized by RMA, and fold enrichment was determined by calculating the ratio 
of the linearized signal intensities of the experimental versus control samples (or 
the negative reciprocal of the linearized signal ratio for values < 1).  Genes with 
fold enrichments either greater than 1.6 or less than -1.6 (in C2C12) and greater 
than 2.0 or less than -2.0 (in hMSCs) were considered significant. Significant 
genes with known functions were manually annotated based on descriptions 
given in the GeneCards database (Safran et al., 2010; available at 




Chromatin immunoprecipitation was carried out as reported (Boyer et al., 2005) 
with some modifications. All lysis steps were carried out at 4˚C with rotation. 
Nuclei were sonicated (Misonix XL-2000) by performing 8 rounds of 3 x 5s pulses 
with at least 20s rest between pulses and 2 min rest between rounds. After 
sonication, lysis with 1% Triton-X was extended to 10 minutes at 4˚C with 
rotation prior to centrifugation. The supernatant was collected and precleared 
with 1µg control IgG bound to protein G Dynabeads (Invitrogen, Carlsbad, CA) 
for 1 hour at 4˚C. The precleared lysate was added to 5µg Flag or control mouse 
IgG antibody bound to protein G Dynabeads and incubated overnight at 4˚C with 
rotation. Washes, elution, and DNA purification were performed as noted. DNA 
was precipitated with ethanol (200 mM NaCl with 8 µg glycogen added to 
facilitate precipitation) and stored at –80˚C overnight. DNA was pelleted by 
centrifugation (13k rpm, 30 minutes), washed 2x with 70% ethanol, and allowed 
to dry before resuspension in 10mM Tris pH 8.0. 
 
Analysis of ChIP DNA by Next-Generation Sequencing 
250ng of ChIP DNA samples were sequenced by the Illumina Genome Analyzer 
II in the Vanderbilt Genome Technology Core. Sample DNA size and 
concentration were measured by Pico Chip and NanoDrop, respectively, followed 
by further sonication to generate DNA sizes between 150-200bp (Bioruptor, 
Diagenode, Denville, NJ; 5 min, low, 30s on and 30s off). Samples were further 
prepared by following the Illumina ChIP preparation protocol, then DNA ranging 
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For RT-PCR analysis, total cellular RNA was isolated as described above, and 1 
µg RNA was used to generate cDNA using the Superscript II Reverse 
Transcriptase kit (Invitrogen) according to the manufacturer‟s protocol.  PCR 
conditions for RT-PCR were as follows: 94˚C for 1 min; 33 cycles of 94˚C for 1 
min, 54˚C (or 56˚C for Ngfr, Dll1, Igf2, Tle4, Fgfr2, Kdm4b, Dkk3, Rarg, and 
Pdgfra) for 1 min, and 72˚C for 1 min 30 sec; 72˚C for 10 min. All PCR reactions 
were carried out using Platinum PCR Supermix (Invitrogen) according to the 
manufacturer‟s protocol. RT-PCR primer sequences are as follows:  
Fgfr2 - Forward 5‟-TGGTCACCATGGCAACCTTGTC-3‟, Reverse 5‟-
TAGCCTCCAATGCGATGCTCCT-3‟; Fgfr3 - Forward 5‟-CCCTCCATCTCC-
TGGCTGAAG-3‟, Reverse 5‟-CACCAGCCACGCAGAGTGATG-3‟; Dll1 - 
Forward 5‟-GCCAGGTACCTTCTCTCTGATC-3‟, Reverse 5‟-TGGTGAGTACA-
GTAGTTCAGGTC-„3; Gli2 - Forward 5‟-GGACAGGGATGACTGTAAGCAG-3‟, 
Reverse 5‟-CTCTTGGTGCAGCCTGGGATCT-3‟; Hoxb5 - Forward 5‟-CGCCAA-
TTTCACCGAAATAGACG-3‟, Reverse 5‟-CAAGATAACCAGTCCAGGAGAGA-
3‟; Wnt4 - Forward 5‟-CAGGTGTGGCCTTTGCAGTGAC-3‟, Reverse 5‟-CACTG-
CCGGCACTTGACGAAG-3‟; Wnt11 - Forward 5‟-GGCCAAGTTTTCCGATGCT-
CCT-3‟, Reverse 5‟-CCCACCTTCTCATTC-TTCATGCA-3‟; Id2 - Forward 5‟-
CGACTGCTACTCCAAGCTCAAG-3‟, Reverse 5‟-CCTTCTGGTATTCACGCTC-
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CAC-3‟; Pth1r - Forward 5‟-TGCACTGCACGCGCAACTACAT-3‟, Reverse 5‟-
CCCTGGAAGGAGTTGAAGAGCA-3‟; Sox9 - Forward 5‟-CCCTTCATGAAGA-
TGACCGACG-3‟, Reverse 5‟-CCGTTCTTCACCGACTTCCTCC-3‟; Tle3 - 
Forward 5‟-CGGTGAAGGATGAGAAGAACCAC-3‟, Reverse 5‟-GTTGGTGTGT-
TGGACTTGAGCC-3‟; Tle4 - Forward 5‟-TCCTGTGATCGGATTAAGGAAGAG-
3‟, Reverse 5‟-GGAGTCTCTGTCTCTTTGGTGAT-3‟; Ngfr - Forward 5‟-
CAGGACTCGTGTTCTCCTGCC-3‟, Reverse 5‟-CCACAAGGCCCACAACCA-
CAG-3‟; Igf2 - Forward 5‟-GGAAGTCGATGTTGGTGCTTCT-3‟, Reverse 5‟-
CTGAACTCTTTGAGCTCTTTGGC-3‟; Myogenin - Forward 5‟-GCCCAGTGAAT-
GCAACTCCCACA-3‟, Reverse 5‟-CTCTGGACTCCATCTTTCTCTCCT-3‟; Tnnt1 
- Forward 5‟-GGCAGAAGATGAGGAAGCGGTG-3‟, Reverse 5‟-CCACGCTTCT-
GTTCTGCCTTGAC-3‟; Kdm4b - Forward 5‟-GGGACTTCAACAGATATGTGG-
CGT-3‟, Reverse 5‟-GCCAGGCAAACGTGGTCTTCCA-3‟; Rarg - Forward 5‟-
CCCGACAGCTATGAACTGAGTCC-3‟, Reverse 5‟-AGGCAGATAGCACTAAGT-
AGCCCA-3‟; Pdgfra - Forward 5‟-GGAGAAACGATCGTGGTGACCTG-3‟, 
Reverse 5‟-CCTGACTCTTCTGTACATCAGTGG-3‟; Dkk3 - Forward 5‟-CCTCC-
CAACTATCACAATGAGACC-3‟, Reverse 5‟-GGTGATGAGATCCAGCAGCTGG-




For ChIP-PCR experiments, ChIP DNA was isolated as described above. Whole 
cell extract DNA was taken from precleared lysates prior to addition of antibody-
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bound beads. PCR conditions for ChIP-PCR were as follows: 94˚C for 5 min; 33 
cycles of 94˚C for 1 min, 56˚C for 1 min, and 72˚C for 3 min; 72˚C for 10 min. 
PCR reactions were carried out using AmpliTaq Gold 360 DNA Polymerase 
(Applied Biosystems) according to the manufacturer‟s protocol. Fgfr2 ChIP 




Immunofluorescent C2C12 and mesenchymal stem cell staining was generally 
performed 2 days post-retroviral (pOZ vectors) or lentiviral infections (shRNA), 
following standard protocols. Cells plated on gelatin (C2C12 and hMSCs)- or 
collagen (SYO-1)- coated cover slips were fixed in 3% para-formaldehyde, 
blocked with 3% goat serum and incubated with the designated primary 
antibodies for 2 hours at room temperatures and 30 minutes with the appropriate 
secondary antibodies (Alexa-Fluor, Invitrogen).1x PBS solution was used for all 
washes. The Zeiss Axioplan2 fluorescent microscope was used for imaging. 
 
Human bone marrow-derived mesenchymal stem cells and differentiation assays 
Adipogenic and osteogenic differentiation assays in the hMSCs were conducted 
according to the Protocol for Expansion of Human MSCs provided by the Institute 
for Regenerative Medicine at Scott and White Hospital (TAMHSCCOM). Oil-Red-
O staining was performed as previously described in (Feldman and Dapson, 
1974). The Alkaline Phosphatase kit from Sigma was used for osteogenic 
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staining. Alizarin Red method was provided by the Institute for Regenerative 
Medicine at Scott and White Hospital (TAMHSCCOM).  
 
Growth inhibition sulforhodamine B (SRB) assay 
Two days after lentiviral FGFR2-shRNA infection, SYO-1 cells were seeded in 
96-well plates at 2x104/well and allowed to grow for two additional days. Or, one 
day after seeding the SYO-1 cells as described above, PD173074 was added for 
a 48 hour-duration. After the indicated times in both experiments, the cells were 
fixed with 10%TCA and stained with SRB to measure protein density at 488 nm 
excitation and 585 nm emission wavelengths following established protocols 
(Vichai and Kirtikara, 2006). 
  
SYT-SSX2 SiRNA  
For SYT-SSX2 depletion in SYO-1 cells, one control (INV) and two SSX2-specific 
(Si-SSX2A and Si-SSX2B) RNA duplexes were used. Successful depletion with 
INV, Si-SSX2A (Pretto et al., 2006), and Si-SSX2B (Lubieniecka et al., 2008) 
was previously reported. siLentFect reagent (BioRAD, Hercules, CA) was used 
for transfections performed according to company protocols. Protein levels in 
cellular lysates and NEF-positivity were quantitated 3 days after siRNA addition.  
  
FGFR2 ShRNA  
Lentiviral human FGFR2-specific ShRNA bacterial stocks were purchased from 
Sigma (NM_000141). The vector that failed to target FGFR2 (2910) was used as 
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a negative control. It contained the following oliogomer: 5‟-CCGGGCCAACCT-
CTCGAACAGTATTCTCGAGAATACTGTTCGAGAGGTTGGCTTTTT-3‟. Two 
lentiviral vectors allowed FGFR2 depletion (clones 833 and 703). They contained 
the following targeting sequences: ShRNA 833: 5‟-CCGGCCCAACAATAGGAC-
AGTGCTTCTCGAGAAGCACTGTCCTATTGTTGGGTTTTT-3‟ and ShRNA 703: 
5‟-CCGGGCCACCAACCAAATACCAAATCTCGAGATTTGGTATTTGGTTGG-
TGGCTTTTT-3‟. The ShRNA lentiviruses were produced in 293T cells as 
previously described (Brown et al., 2009). 20 µg of lentiviral DNA were used to 
transfect one 100mm plate of 293T cells. 48 hours post-transfection, the viruses 
were harvested and used to infect hMSCs and SYO-1 cells for a 6-hour duration 
with added polybrene. The hMSCs were routinely infected with the FGFR2-
shRNA vectors 24 hours after prior transduction with the pOZ and pOZ-SYT-
SSX2 retroviral vectors. Effects of shRNAs on FGFR2 levels and NEF 
expression in hMSCs and SYO-1 cells were measured 2 days and 3 days post-
lentiviral infection, respectively. 
 
Generation of bacterial expression plasmids 
The bacterial expression plasmids pLM302 and pLM302-yTAF12 were kind gifts 
from P.A. Weil. Human Ring1b, mouse Bmi1, and human SYT-SSX2 were PCR 
amplified with the following primers:  
Ring1b-forward 5‟-GCGCGGATCCTCTCAGGCTGTGCAGACAAAC-3‟, Ring1b-





GCGCCTCGAGTTACTCGTCATCTTCCTCAGGGTCGC-3‟. Amplified fragments 
were digested with BamH1 and Xho1 (Ring1b and Bmi1) or EcoR1 and Xho1 
(SYT-SSX2), gel purified, and ligated into pLM302. Ligation products were 
transformed into E.coli DH5 and plated on kanamycin-containing (50 µg/mL) 
selection plates. Colonies were screened for the presence of the appropriate 
insert and then sequenced. 
 
2PY-Bmi1 immunoprecipitation and -phosphatase assay 
MG132- or DMSO-treated C2C12 cells expressing 2PY-Bmi1 were lysed in 20 
mM Tris pH 8.0, 150 mM NaCl, 0.5% NP-40, plus protease and phosphatase 
inhibitors for 30 minutes at 4˚C with rotation. Cellular debris was pelleted by 
centrifugation (13k rpm, 4˚C, 15 minutes), and the supernatant was collected. 1 
µL Glu-Glu antibody was added to each supernatant and rotated for 2h at 4˚C, 
and antibody-bound proteins were captured with rabbit antiserum to mouse IgG 
(whole molecule, Cappel) for 0.5h at 4˚C then protein A sepharose (GE 
Healthcare Bio-sciences, Piscataway, NJ) for 0.5h at 4˚C. Beads were washed 
twice with lysis buffer lacking inhibitors then once with lysis buffer plus protease 
inhibitors. Wash buffer was aspirated and the samples were stored on ice during 
-phosphatase preparation. Reaction buffer was prepared in separate tubes 
according to the manufacturer‟s protocol (NEB, Ipswich, MA) plus 10 µL/mL 
aprotinin and 10 µL/mL leupeptin with and without 5 mM NaF and 10 mM NaOV. 
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500 U phosphatase were added to each tube containing reaction buffer and 
activated by incubation at 30˚C for 2 minutes. Enzyme-reaction mixture was 
added to the immunoprecipitated material and incubated at 30˚C for 2h with 
intermittent mixing. Reactions were quenched by the addition of 2x sample buffer 
and stored at -20˚C. Samples were analyzed by SDS-PAGE without boiling to 
prevent the dissociation of the antibody chains. 
 
Purification of bacterially-expressed Ring1b, Bmi1, and SYT-SSX2 
Expression vectors were transformed into Rosetta 2(DE3)pLysS competent 
E.coli (Novagen, Rockland, MA) according to the manufacturer‟s protocol and 
grown on kanamycin/chloramphenicol (50 ug/mL kanamycin, 34 ug/mL 
chloramphenicol) selection plates. All subsequent growth and induction steps 
were performed at 25˚C. Single colonies were inoculated in LB containing 
antibiotics and grown overnight. For Bmi1 and Ring1b, overnight cultures were 
diluted 1:20 into fresh LB, grown for 2 hours then induced with 0.5 mM IPTG for 4 
hours. For SYT-SSX2, 1:20 dilution of overnight cultures was grown for 4h then 
induced with 0.1 mM IPTG overnight. After induction, bacteria were pelleted and 
resuspended in buffer (20 mM Tris 7.5, 150 mM NaCl or 300 mM NaCl for Bmi1). 
Bacteria were treated with lysozyme (0.75 mg/mL) for 20 minutes on ice, 
subjected to 2 freeze/thaw cycles, then centrifuged for 1 hour at 12k rpm at 4˚C. 
Glycerol was added to the supernatants to a final concentration of 10% (v/v), and 
the crude extracts were snap frozen in a dry ice/ethanol bath and stored at -80˚C. 
Amylose resin (NEB) was washed with bacterial resuspension buffer, and crude 
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extracts were added to pre-washed resin. Proteins were allowed to bind for 30 
minutes at 4˚C with rotation and eluted using 10 mM maltose added to 
resuspension buffer. An aliquot of eluate was reserved to measure protein 
concentration before the addition of glycerol (10% v/v final concentration), snap 
freezing, and storage at -80˚C.  
 
Nucleosome isolation 
Nucleosomes were prepared as described by Hernández-Muñoz et al, 2005. 
C2C12 or HeLa cells were washed 3 times with 1x PBS then harvested and 
pelleted at 2k rpm, 4˚C for 10 minutes. Cells were resuspended in 2 packed cell 
volumes of buffer containing 10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 
0.5 mM DTT and incubated on ice for 10 minutes. Cell suspensions were 
transferred to a Dounce homogenizer and lysed with 10 strokes using a loose 
pestle. The cell lysates were then centrifuged for 5 minutes at 2.8k rpm (750 x g), 
4˚C. Pellets were resuspended in buffer containing 50 mM Tris pH 7.5, 0.34 M 
sucrose, 3 mM CaCl2, 60 mM KCl, 0.5 mM PMSF, 0.4 mM benzamidine, 10 µM 
leupeptin, and 1 µg/mL aprotinin. The DNA was digested using micrococcal 
nuclease (NEB; 325 U/mL lysate) at 37˚C for 10 minutes, and the reaction was 
quenched by adding EGTA to a final concentration of 0.05 mM. The extracts 
were further lysed by Dounce homogenization (100 strokes, tight pestle) followed 
by the addition of 500 mM NaCl (final concentration). Cellular debris was pelleted 
(12.1k rpm [14k x g], 4˚C, 20 minutes), and the supernatant was dialyzed 
overnight against 20 mM HEPES pH 7.5, 2 mM EDTA, 2 mM EGTA, 650 mM 
 33 
NaCl, 1 mM -mercaptoethanol, 0.5 mM PMSF, 2 mM benzamidine, and 16 mM 
-glycerophosphate. 2x sample buffer was added to an aliquot of nucleosome 
extract and analyzed by western blotting for the presence of H2A, H2B, H3, and 
H4. To check DNA digestion, nucleosome extracts were diluted to 150 mM NaCl, 
20 mM HEPES pH 7.5, 2 mM EDTA, and 2 mM EGTA. 20µg proteinase K was 
added, and the extracts were incubated overnight at 55˚C. The next day, the 
DNA was purified by phenol:chloroform extraction and precipitated overnight with 
ethanol (200 mM NaCl and 1µg glycogen were added to facilitate precipitation) at 
-80˚C. The DNA was pelleted, washed with 70% ethanol, and air dried before 
resuspension in TE and analysis by gel electrophoresis.  
 
Preparation of nuclear extracts 
Naïve, pOZ-, or SYT-SSX2-expressing C2C12 cells were washed 3 times with 
and harvested in 1x PBS (48 hours post-infection for pOZ and SYT-SSX2 
samples). Cells were collected by pulse-spinning and washed once with 
hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
DTT). The cells were then incubated in 2 packed cell volumes of hypotonic buffer 
for 10 minutes on ice. Cells were lysed by the addition of 2 µL 5% NP-40 and 
gentle mixing 5 times by pipet. Nuclei were pelleted by pulse-spinning then lysed 
in buffer containing 2 0mM Tris pH 8.0, 300 mM NaCl, 0.5% NP-40, 10% 
glycerol, and protease/phosphatase inhibitors for 20 minutes at 4˚C with rotation. 
Nuclear debris was pelleted by centrifugation (13k rpm, 15 minutes, 4˚C), and 
supernatants were flash frozen and stored at -80˚C. 
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In vitro ubiquitylation assay 
Ubiquitylation assays were performed as described previously (Cao et al., 2005) 
with some modification. Bacterially purified Ring1b and Bmi1 were added 
individually or in complex (equimolar amounts of Ring1b and Bmi1 were 
incubated together on ice for 10-15 minutes) to an ubiquitylation reaction mixture 
containing 50 mM Tris pH 7.9, 5 mM MgCl2, 2 mM NaF, 0.6 mM DTT, 2 mM ATP, 
10 µM okadaic acid, 0.1 µg recombinant human ubiquitin-activating enzyme (E1, 
Calbiochem, La Jolla, CA), 0.6 µg recombinant human UbcH5c (E2, 
Calbiochem), and 1 µg FLAG-ubiquitin (Sigma, St. Louis, MO). Bacterially 
purified SYT-SSX2, pOZ- or SYT-SSX2-expressing cell nuclear extracts, and/or 
5 µg of HeLa nucleosomes were added as indicated. Reactions were incubated 





 All microarray and ChIPSeq data are available at the Gene Expression Omnibus 
(available at www.ncbi.nlm.nih.gov/geo/; Edgar et al., 2002) accessions 
GSE26562 (C2C12 microarray), GSE26563 (hMSC microarray, GSE26564 





Analysis of SYT-SSX2 ChIPSeq 
The Illumina Analysis Pipeline was used for image analysis and base calling. 
Sequence reads from the control IgG ChIP and SYT-SSX2 ChIP were aligned to 
the mouse genome using Bowtie (Langmead et al., 2009) utilizing the “--best” 
option to generate SAM files for each condition. The output SAM files were used 
as the input for the Model-based Analysis of ChIPSeq (MACS) program (Zhang 
et al., 2008) to determine peak regions in SYT-SSX2-expressing cells using 
default parameters except “--mfold” was 16. For each peak, the distance to the 
nearest gene was calculated based on the position of the 5‟ end of the peak and 
transcription start sites annotated in the UCSC Genome Browser (July 2007, 
build mm9) (Kent et al., 2002; Fujita et al., 2010).  
 
Cross-validation of C2C12 Microarray with ChIPSeq 
Distances to the nearest upstream and downstream peaks were determined for 
each significantly upregulated gene of the C2C12 microarray. Distances were 
determined by calculating the average distance between the transcription start 
site annotated for the given RefSeq accession (Pruitt et al., 2007) and the 
nearest peak summit. 
 
Motif Analysis 
ChIPSeq peaks within 10kb upstream of transcription start sites of upregulated 
genes were utilized for motif analysis. Repeat elements were masked using the 
DUST program (Morgulis et al., 2006) prior to motif search analysis using MEME 
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using default parameters (Bailey and Elkan, 1994). The position-specific 
probability matrix derived from MEME was used as input for the TOMTOM 
program (used with default parameters) to determine potential transcription factor 
binding sites within the motifs (Gupta et al., 2007). 
 
Overlap of SYT-SSX2 with histone modifications, DNA methylation, and PolII in 
C2C12 cells 
Previously published ChIPSeq datasets for ubiquitylated histone H2B (H2BUb); 
mono-, di-, and trimethylated histone H3 lysine 4 (H3K4me1/2/3); acetylated 
histone H3 lysine 9 (H3K9Ac), lysine 18 (H3K18Ac), and histone H4 lysine 12 
(H4K12Ac); trimethylated histone H3 lysine 27 (H3K27me3) and lysine 36 
(H3K36me3); and RNA polymerase II (PolII) were downloaded from the Gene 
Expression Omnibus (GEO) accession GSE25308 (Asp et al., 2011). MeDIP-
ChIP data were obtained from GEO accession GSE22077 (Hupkes et al., 2011). 
Overlapping regions between individual datasets and SYT-SSX2 were 
determined using the Coverage and Intersect tools from the Galaxy program 
(available at http://main.g2.bx.psu.edu/) (Giardine et al., 2005; Goecks et al., 
2010; Blankenberg et al., 2010). 
 
Association of SYT-SSX2 ChIPSeq peaks with gene expression 
SYT-SSX2 peaks were annotated to the nearest downstream gene on both 
strands by measuring the distance from the 5‟ end of the peak to the gene 
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transcription start site (TSS). Peaks associated with differentially expressed 
genes were identified. 
 
Hierarchical clustering 
Differentially regulated genes containing overlapping sites between SYT-SSX2 
and specific epigenetic markers within the gene and up to 50kb upstream of the 
TSS were used in the clustering analysis. For each gene, coverage ratios (the 
number of bases covered by overlapping regions divided by the total number of 
bases in a given window) for the gene body and for 5kb bins upstream of the 
TSS (up to 50kb) were calculated for each epigenetic marker. These coverage 
ratios served as the input data for the clustering analysis. Hierarchical clustering 
was performed separately for up- and downregulated genes using Cluster 3.0 (de 
Hoon et al., 2004) with gene and array clustering. The similarity metric used was 
Spearman Rank Correlation, and the clustering method used was centroid 
linkage. The output file was uploaded to Java Treeview (Saldanha, 2004) for 









 SS tumors display a wide spectrum of phenotypes including 
characteristics of neural, mesenchymal, and epithelial differentiation (Ladanyi, 
2001; Ishibe et al., 2008; Naka et al., 2010).  SS tumor cell lines exhibit limited 
differentiation potential implying a stem cell origin for this malignancy (Ishibe et 
al., 2008; Naka et al., 2010). One study revealed that SYT-SSX silencing in SS 
cells permits their differentiation into multiple mesenchymal lineages, while 
another group was able to show neuronal differentiation after treatment with 
FGF2 or ATRA (all-trans retinoic acid), supporting the hypothesis that SS arises 
in human multipotent stem cells (Naka et al., 2010, Ishibe et al., 2008). 
Deregulation of normal differentiation driven by SYT-SSX is therefore believed to 
be the basis for transformation that leads to cancer development (Naka et al., 
2010). However, it remains to be determined how SYT-SSX expression affects 
the differentiation of normal somatic stem cells. Another interesting facet to this 
issue is the question of whether SYT-SSX itself confers plasticity on its target cell 
or if the plasticity of the tumor cells is solely a reflection of multipotency in the 
cell-of-origin. Elucidating the nuances of this topic will be crucial in developing 
effective therapies for SS with minimal repercussions to normal tissues. 
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 Recent efforts have focused on determining the cell-of-origin for SS since 
it is still unclear what cell type is involved the formation of SS tumors. 
Distinguishing these target cells is of particular interest since knowledge of their 
identity may lead to the development of more effective therapies. It is generally 
believed that SS arises from a mesenchymal stem or progenitor cell (Mackall et 
al., 2004); however, investigations into the ability of SS tumor cells to differentiate 
into multiple lineages have confounded this issue (Naka et al., 2010; Ishibe et al., 
2008). Tumors display increased expression of genes associated with neural 
functions like axon growth and signaling suggesting that SS is derived from 
neural crest cells. The disparate sites of tumor growth also imply that the 
originating cell may be of neural crest lineage. Treatment of cell lines with ATRA 
or FGF2 leads to neuronal differentiation adding additional support to this 
hypothesis (Ishibe et al., 2008). In contrast, tumor cell lines express osteogenic, 
chondrogenic, adipocytic, and hematopoietic markers, and knock-down of the 
oncogene causes the expression of additional mesenchymal and hematopoietic 
markers and the adoption of a morphology resembling that of MSCs. Moreover, 
these cells could also be induced to differentiate into mesenchymal lineages and 
macrophage-like cells with the efficiency of differentiation increasing after knock-
down of SYT-SSX1. These results implicate the transformation of a multipotent 
stem cell with both mesenchymal and hematopoietic potential (Naka et al., 2010). 
While tissue-specific stem cells with this spectrum of differentiated lineages have 
not been discovered, neural crest-derived stem cells have the capacity to 
differentiate into mesenchymal lineages, and MSCs can be induced to form 
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neurons indicating that these cell populations are capable of forming cell-types 






SYT-SSX2 expression deregulates developmental programs and differentiation 
in myoblasts 
SYT-SSX expression is sufficient to drive tumorigenesis (Nagai et al., 
2001; Haldar et al., 2007) and previous studies show that SYT-SSX fusions 
might alter the differentiation potential of synovial sarcoma cells (Naka et al., 
2010; Ishibe et al., 2008). What has been lacking, however, is a thorough 
analysis of the initial changes that occur in the mesenchymal precursor cell when 
SYT-SSX is expressed. We chose to conduct such analysis in C2C12 myoblasts 
because they are a well-characterized, untransformed system of mesenchymal 
lineage capable of differentiation into multiple cell types (Odelberg et al., 2000). 
Additionally, in a transgenic synovial sarcoma model, SYT-SSX2 expression in 
muscle progenitors formed tumors that recapitulated the human disease (Haldar 
et al., 2007), further indicating that myoblasts are a relevant model system.    
 After confirming their myogenic identity with a marker profile and myotube 
formation (Appendix B Figure B1), we transduced C2C12 myoblasts with HA-
Flag-SYT-SSX2 or vector control to define their genetic programs. The 
microarray analysis generated 700 upregulated and over 800 downregulated 
genes. Comparison of this data to a microarray of 8 human synovial sarcomas 
(Nielsen et al., 2002) identified nearly 100 upregulated genes shared between 
SYT-SSX2-myoblasts and human tumors (Appendix B Table B1). Strikingly, 




Sox9) and mediators of developmental pathways such as FGF (Fgfr2 and Fgfr3), 
Notch (Dll1), Hedgehog (Gli2), and Wnt (Tle4) (Figure 2A). Their expression was 
validated by RT-PCR (Figure 2A, asterisks). Furthermore, upregulation of various 
Wnt ligands, (Figure 2A, Wnt4 and Wnt11; Nielsen et al., 2002) in both SYT-
SSX2-myoblasts and human SS tumors reflected a sustained activation of this 
pathway.   
An overall functional categorization of the upregulated genes revealed 85 
(12.2%) to be involved in development (Figure 2B), the majority of which function 
in lineage specification (Appendix B Table B2). Similarly, 85 (12.6%) of the 
downregulated genes are involved in differentiation and development (Figure 
2B). Most striking, however, was the upregulation of 166 genes (23.9%) normally 
involved in neural differentiation and function (Figure 2B and Appendix B Table 
B3). Notably, we observed a simultaneous downregulation of 52 (7.7%) 
myogenic genes (Figure 2B), including terminal differentiation markers (troponin 
and muscle-specific myosins) as well as transcriptional controllers of myogenesis 
(Myf5, MyoD, and myogenin; Appendix B Table B4 and Figure B2A). These data 
suggested a block of myogenic differentiation that was confirmed when SYT-
SSX2-expressing myoblasts failed to form multinucleated myotubes and 
continued to grow as mononucleated cells (Appendix B Figure B1). Altogether, 
SYT-SSX2 expression in myoblasts led to the abrogation of myogenesis with an 




Targeting of SYT-SSX2 to chromatin is required for occupancy of neural genes 
and induction of the neural phenotype  
To identify the specific subset of genes to which the SYT-SSX2 complex is 
recruited, we conducted ChIP-Sequencing (ChIPSeq) analysis and determined 
the genome-wide occupancy of SYT-SSX2. We used myoblasts transduced with 
HA-Flag-SYT-SSX2 due to lack of an appropriate antibody that efficiently 
recognizes native SYT-SSX2 epitopes in ChIP experiments. ChIPSeq for SYT-
SSX2 yielded over 19 million unique tags compared with over 16 million unique 
tags in the control. Putative SYT-SSX2 target sites were determined by the 
Model-based Analysis of ChIPSeq (MACS) program. This analysis validates true 
peaks by calculating the significance of each candidate peak relative to the 
control using a significance threshold (Zhang et al., 2008). In our study, this 
method generated approximately 53,000 peaks with a maximum false discovery 
rate of 2.8%. The ChIP peaks were categorized by their distance upstream of 
transcription start sites (TSS, +1) and the results are shown in Table 1. On the 
whole, the majority of peaks (approximately 60%) are located at distances 
greater than 50kb from TSS. Closer to known genes, 20% of the peaks are 
located within 20kb upstream of TSS, with over 6000 sites (11.5% of the total 
peaks) between 0-10kb (Table 1). 3440 sites are located within 5kb upstream of 
TSS corresponding to 1352 genes (Table 1). As an extension of this data, we 
also found that SYT-SSX2 bound within a total of 3,290 genes and exclusively 
within the body of 821 genes. Given that SYT-SSX2 associates with transcription 
regulators, we decided to analyze more closely the genes with SYT-SSX2 
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occupancy near their TSS. As a starting point, we selected the genes with SYT-
SSX2 peaks situated up to 10kb upstream of their TSS, in the event the 
oncogene, like other known transcription regulators, binds beyond the traditional 
promoter region (Farnham, 2009). Moreover, by nature of their function, the 
Polycomb and SWI/SNF chromatin modifying complexes SYT-SSX2 associates 
with, may direct its docking at sites farther from the traditional 5 kb proximal 
regulatory region (Mateos-Langerak and Cavalli, 2008).   
 
Table 1. Distribution of  SYT-SSX2 ChIP peaks relative to gene  
transcription start sites and corresponding genes. 




Total number of 
genes 
0-5kb 3440 6.5 1352 
5-10kb 2654 5.0 1076 
10-15kb 2400 4.5 1016 
15-20kb 2287 4.3 933 
20-50kb 10230 19.3 2026 
50-100kb 10312 19.5 1693 
100-150kb 6035 11.4 973 
150-200kb 3956 7.5 659 




Focusing on the window 10kb upstream of gene TSS, cross-validation of 
the microarray with the ChIPSeq data revealed that SYT-SSX2 was physically 
recruited to approximately 200 of the upregulated genes and to only 51 of the 
downregulated genes. Functionally, the downregulated 51 genes followed the 
general distribution of genes in the overall microarray (Appendix B Figure B2B). 
Strikingly, genes associated with neural development and function, were quite 
prevalent (42.8%; 68 genes) among the 200 upregulated genes bound by the 
SYT-SSX2 complex (Figure 3A). These genes are active in different aspects of 
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neural differentiation including patterning, axon guidance, signaling, and growth 
(Table 2). This is remarkable as C2C12 cells are mesenchymal progenitors and 
do not naturally differentiate into neural lineages.    
  
Table 2. Selected list of upregulated genes bound by the SYT-SSX2 complex involved in 
neural development and function. 
Symbol Gene Description Symbol Gene Description 
Development and Differentiation 
Bhlhe23 basic helix-loop-helix, e23 Fezf2 Fez family zinc finger 
L1cam cell adhesion molecule Olig2 oligodendrocyte lineage factor 
Prox1 prospero homeobox Ptpru protein tyrosine phosphatase 
Zcchc12 zinc finger with CCHC domain Zic2 Zinc finger protein of cerebellum 
Patterning and Axon Guidance 
Crmp1 collapsin response mediator Dpysl5 dihydropyrimidinase-like 5 
Epha8 Eph receptor A8 Efnb1 ephrin B1 
Ephb1 Eph receptor B1 Slit3 slit homolog 3  
Unc5a Netrin receptor    
Neurotransmitter Signaling and Metabolism 
Abat aminotransferase Adra2c adrenergic receptor 
Cacna1h calcium channel  Cacng5 calcium channel 
Chrna4 cholinergic receptor Grm4 glutamate receptor 
Kcnip3 Kv channel interacting protein 3 Nptx1 neuronal pentraxin 1 
Slc6a1 GABA transporter Th tyrosine hydroxylase 
Neuropeptide, Lipid, and Hormone Signaling 
Cck cholecystokinin Faah fatty acid amide hydrolase 
Gpr50 G protein-coupled receptor 50 Gal galanin 
Mgll monoglyceride lipase Ntsr1 neurotensin receptor 1 
Pdyn prodynorphin Sst somatostatin 
Adhesion, Growth, and Survival 
Amigo2 adhesion molecule Bai1 brain angiogenesis inhibitor 1 
Bai2 brain angiogenesis inhibitor 2 Cdh23 cadherin 23 




 Further analysis of the ChIPSeq peaks located upstream of the 200 genes 
(approximately 500 peaks total) derived a recruitment motif for SYT-SSX2 rich in 
C and T residues (Figure 3B, first column) and contained in one hundred thirty-
two (132) peaks. This motif contains potential binding sites for a group of 
transcription factors belonging to the homeodomain, nuclear receptor, and Sp1 




and differentiation. The extensive association of SYT-SSX2 with neural genes led 
us to question if these myoblasts exhibited a matching phenotype. In a 
background of 80% to 90% infection efficiency, 40% of SYT-SSX2-myoblasts 
expressed neurofilament (NEF, Figure 3C, middle row, right panel and 
histogram), while control cells showed minimal (< 2%) neurofilament staining 
(Figure 3C, top row, right panel). The empty vector produces a short HA-Flag-
peptide that allows the visualization of positively infected control cells (Figure 3C, 
top row, middle panel). Moreover, oncogene-expressing cells exhibited long 
projections (Figure 3C, arrow), similar to a phenotype we observed in SYT-
SSX2-expressing fibroblasts (Barco et al., 2007) and consistent with the 
neurogenic features noted in synovial sarcoma cells (Ishibe et al., 2008). Overall, 
stimulation of a pro-neural program appears to be a pronounced feature of SYT-
SSX2.   
Mediators of differentiation including the Wnt, Hedgehog, and FGF 
pathways formed an additional 11.9% (19 genes) of the 200 genes occupied by 
SYT-SSX2 (Figure 3A; Appendix B Table B2, asterisks). In particular, we noticed 
the presence of FGF mediators throughout our analyses. By microarray, a 
number of FGF pathway members were upregulated (Appendix B Table B2), and 
increased expression of FGF receptors Fgfr2 and Fgfr3 was confirmed by RT-
PCR (Figure 2A). Importantly, the same FGFR2 and FGFR3 were also 
upregulated in human synovial sarcomas (Appendix B Table B1; Nielsen et al., 
2002). ChIPSeq analysis indicated that the Fgfr2 gene is directly targeted by 
SYT-SSX2, and further ChIP experiments confirmed the presence of SYT-SSX2 
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at the peak located 4.3 kb upstream of the Fgfr2 gene (Figure 3D, ChIP-PCR 
panel). Notably, the Fgfr2 peak contains a sequence matching the SYT-SSX2 
recruiting motif (Figure 3B). Thus, the FGF receptor appears to be a direct target 
of the oncogene.  
SYT-SSX2 associates with Polycomb complexes, modulators of chromatin 
and lineage determination. To determine whether the ability of SYT-SSX2 to 
target chromatin is required for the observed effects, we tested SXdel3, a SYT-
SSX2 mutant with a twenty-residue deletion in its SSX-targeting module (Figure 
3C, diagram). SXdel3 is unable to co-localize with Polycomb and antagonize its 
Bmi1 component in U2OS cells (Barco et al., 2009). When assayed in C2C12 
cells, SXdel3 failed to induce neurofilament formation (Figure 3C, bottom row, 
right panel), indicating an inactive neural program. Furthermore, we observed 
that the ability of SXdel3 to upregulate FGFR2 expression (Figure 3D, RT-PCR 
panel), or bind upstream of the gene (Figure 3D, ChIP-PCR panel and 
histogram), was markedly diminished. To summarize, these studies demonstrate 
that SYT-SSX2 activates a pro-neural program and blocks normal myogenesis. 
Its ability to bind chromatin is required for its transcriptional and phenotypic 
effects. 
 
SYT-SSX2 causes aberrant differentiation in human mesenchymal stem cells 
 Myoblast reprogramming by SYT-SSX2 prompted us to question whether 
dictating lineage commitment in undifferentiated precursors is an intrinsic feature 




cell (Naka et al., 2010; Mackall et al., 2004), we questioned whether SYT-SSX2 
expression could elicit similar effects in multipotent, human bone marrow-derived 
mesenchymal stem cells (hMSCs; Colter et al., 2001; Sekiya et al., 2002; 
Appendix B Figure B3). Searching for a neural phenotype in SYT-SSX2-hMSCs, 
we observed a robust and heterogeneous NEF expression in a significant 
population (Figure 4A, bottom row, right panel and arrowheads). Neither naïve 
nor vector-hMSCs produced neurofilaments (Figure 4A, top and middle rows, 
right panels). 
 We next asked whether SYT-SSX2 influenced the ability of hMSCs to 
differentiate into their normal lineages. We discovered that oncogene expression 
caused a marked inhibition of adipogenesis, while naïve and vector-expressing 
cells differentiated normally (Figure 4B, top row). In contrast, SYT-SSX2 
expression accelerated osteogenesis as evidenced by an intense alkaline 
phosphatase staining 48 hours post-infection without added osteogenic factors 
(Figure 4B, bottom row, right panel). As expected, in the absence of inducing 
factors, naïve and vector-expressing hMSCs showed minimal alkaline 
phosphatase staining, (Figure 4B, bottom row, left and middle panels). Alkaline 
phosphatase positivity was heterogeneous (Figure 4B, arrow), indicating that the 
early osteogenesis was activated at varying degrees across the cell population. 
Inhibition of adipogenesis and acceleration of osteogenesis by SYT-SSX2 were 
observed in two additional hMSCs lines, one human (Appendix B Figure B4), and 
one murine (Alfaro et al., 2008; data not shown). Altogether, these data suggest 
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that SYT-SSX2 induces a neural and/or osteogenic program(s) in hMSCs, while 
inhibiting their adipogenic differentiation. 
 
 
Table 3. Selected list of genes involved in neural development and function upregulated by 
SYT-SSX2 in human mesenchymal stem cells. 
Asterisks (*) denote upregulated genes in hMSCs that are also occupied and upregulated by 
SYT-SSX2 in C2C12 myoblasts. 
Symbol Gene Description Symbol Gene Description 
Development and Differentiation 
ENC1 ectodermal-neural cortex EYA4 eyes absent homolog  
FGF11 fibroblast growth factor 11 GBX2 brain homeobox 2 
L1CAM* cell adhesion molecule NEUROD1 neurogenic differentiation 
NEUROG3 neurogenin 3 PROX1* prospero homeobox 1 
Patterning and Axon Guidance 
CRMP1* collapsin response mediator DPYSL5* dihydropyrimidinase-like 5 
EFNA4 ephrin-A4 EFNB1* ephrin-B1 
EPHA3 EPH receptor A3  EPHB1* EPH receptor B1 
GLDN gliomedin NRP2 neuropilin 2 
ROBO1 roundabout SEMA3D semaphorin 
SLIT1 slit homolog 1  UNC5A* netrin receptor 
Neurotransmitter Signaling and Metabolism 
ABAT* aminotransferase ADRA1D adrenergic, receptor 
CHRNA4* cholinergic receptor DRD2 dopamine receptor D2 
GABRE GABA receptor, epsilon GATM glutamate decarboxylase  
GRIK3* glutamate receptor GRM4* glutamate receptor 
metabotropic 
SLC18A3* acetylcholine transporter   
Neuropeptide, Lipid, and Hormone Signaling 
CRHR1* neuropeptide receptor GAL* galanin  
GPR50* G protein-coupled receptor 50 NPY neuropeptide Y 
NTSR1* neurotensin receptor 1 PCSK1 convertase subtilisin/kexin 
PNOC pronociceptin SST* somatostatin 
Adhesion, Growth, and Survival 
AREG amphiregulin BAI2* brain angiogenesis inhibitor 2 
GFRA2 GDNF receptor GPC4 glypican 4 
NCAM1 neural cell adhesion molecule 1 NGFR* nerve growth factor receptor 




A full characterization of the gene expression profiles initiated by SYT-
SSX2 in hMSCs identified approximately 750 significantly upregulated and more 
than 500 significantly downregulated genes when compared to vector-transduced 
hMSCs. Functional categorization of the upregulated genes revealed nearly one  
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Table 4.  Selected list of developmental pathway mediators upregulated by SYT-SSX2 in 
human mesenchymal stem cells. 
Asterisks (*) denote upregulated genes in hMSCs that are also occupied and upregulated by 




third (27.8%) participate in neural differentiation and signaling (Figure 4C and 
Table 3). Notably, several of these genes were also shown to be occupied and 
upregulated by SYT-SSX2 in myoblasts (Table 3, asterisks).  This implies that 
SYT-SSX2 targets the same genes and promotes neural programs regardless of 
cell type. By contrast, promoters of osteoblast differentiation (BMP2, BMP6, 
FGFR3, and OSR2) represented 1.9% of the upregulated genes (Figure 4C and 
Symbol Gene Description Symbol Gene Description 
WNT 
AXIN2* conductin, axil SFRP1 secreted frizzled-related protein 
DACT1 antagonist of b-catenin TLE1 transducin-like enhancer 
protein 
FZD3 frizzled homolog TLE2 transducin-like enhancer 
protein 
FRZB frizzled-related protein TLE3 transducin-like enhancer 
protein 
KREMEN1 kringle containing protein WNT4 WNT ligand 4 
LEF1 lymphoid enhancer-binding 
factor 
WNT7B WNT ligand 7B 
PRICKLE1 prickle homolog  WNT11 WNT ligand 11 
RSPO1 R-spondin homolog   
NOTCH 
DLL1 delta-like JAG1 jagged 1 
DTX1 deltex homolog JAG2 jagged 2 
DTX4 deltex 4 homolog LFNG lunatic fringe 
HES1 hairy and enhancer of split NOTCH1 notch homolog 
HEY2 HES-related with YRPW motif SIX1 SIX homeobox 
TGFb/BMP 
BAMBI BMP and activin inhibitor FAM46C family with sequence similarity 
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BMP3 BMP ligand 3 FSTL4 follistatin-like 
BMP4 BMP ligand 4 GDF6 growth differentiation factor 
BMP7 BMP ligand 7 SOST sclerosteosis 
BMPER BMP binding endothelial 
regulator 
TGFB2 transforming growth factor, 
beta 
SHH 
PTCH1 patched homolog 1 PTCHD2 patched domain 2 
PTCHD1 patched domain 1  SHH* sonic hedgehog homolog 
FGF 
FGFBP2 FGF binding protein 2 FGFR2* fibroblast growth factor 
receptor 2 
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Appendix B Table B5). Taken together, these data suggest that SYT-SSX2 
indeed activates programs of neural and osteogenic differentiation in hMSCs. 
Stem cell controllers such as Wnt, Notch, TGF/BMP, Shh, and FGF 
(Figure 4C and Table 4) constituted 16% of the upregulated genes. 3 of these 
genes, AXIN2, SHH, and FGFR2, were also upregulated and occupied by SYT-
SSX2 in myoblasts (Table 4, asterisks). 
Notably, the C2C12 and the hMSC microarrays overlapped with 248 
differentially expressed genes, 85 (34%) of which belonged to the neurogenic 
program, and 54 (~22%) were developmental mediators and transcription factors 
(Appendix B Table B6).    
 
The role of FGFR2 in SYT-SSX2 differentiation effects  
Throughout our analyses Fgfr2 held our interest as it was noticeably 
upregulated not only in hMSCs and myoblasts but also in human synovial 
sarcoma tumors (Nielsen et al., 2002). Moreover, our ChIPSeq analysis revealed 
Fgfr2 as a direct target of SYT-SSX2. Importantly, FGFR2 is a major inducer of 
both osteogenesis and neurogenesis during development (Huang et al., 2007; 
Villegas et al., 2010) and could be contributing, in part, to the shift in lineage 
commitment seen in human MSCs. FGFR2 was, therefore, our prime candidate 
for an upstream signaling pathway whose activation would explain induction of 
the neural cascade by SYT-SSX2. To assess the contribution of FGFR2 to the 
visible effects of SYT-SSX2, we decided to analyze the consequences of its 
inhibition in the stem cells. Neurofilament formation and cell growth were both 
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used as read-outs to measure the dependence of SYT-SSX2-hMSCs on FGFR2. 
We started by inhibiting FGFR activity with PD173074, a small molecule with 
high selectivity for the FGFR kinase (Pardo et al., 2009). A two-day treatment 
with PD173074 led to a marked diminution of NEF signal in SYT-SSX2-hMSCs 
(Figure 5A, left histogram), reflecting the dependence of the neural marker on 
active FGFR. More specifically, infection of SYT-SSX2-hMSCs with two FGFR2-
specific shRNA vectors (833 and 703, Figure 5A, right panel) exhibited significant 
growth retardation when compared to a non-targeting vector (2910; Figure 5A, 
right histogram, dark grey bars). Apart from growth inhibition, FGFR2 depletion 
caused a specific attenuation of the NEF signal in the SYT-SSX2-hMSCs (more 
pronounced in 703; Figure 5A, right histogram, light grey bars). Importantly, the 
2910, 833 and 703 vectors did not affect the growth of vector-control hMSCs. 
These findings suggest that FGFR2 signaling is required for the proper growth of 
SYT-SSX2-mesenchymal stem cells and the expression of neural differentiation 
markers.  
 We then repeated these analyses in the human SYO-1 synovial sarcoma 
cells that carry the SYT-SSX2 translocation (Kawai et al., 2004). We observed 
that approximately 15% of the SYO-1 cell population contained NEF, and 
PD173074 caused a graded disappearance of NEF-positive SYO-1 cells and an 
incremental inhibition of their growth (Figure 5B, left and middle panels). As in 
the SYT-SSX2-hMSCs, FGFR2 depletion with the 833 and 703 shRNAs also led 
to a marked decrease in the number of NEF-positive SYO-1 cells as well as a 




Figure 5. Contribution of FGFR2 to SYT-SSX2 differentiation effects and to cell growth 
A) Loss of neurite extensions and NEF signal intensity after inhibition of FGF signaling in 
SYT-SSX2 (HA-positive) hMSCs. Top left image depicts a reference NEF (red)-positive SYT-
SSX2-hMSC. Left histogram represents the average ratio of NEF-positive to HA-positive 
cells 2 days post-treatment with PD173074 at the indicated concentrations (n=4; 
approximately 1000 cells were included for each concentration). D is vehicle DMSO. Error 
bars denote standard deviation. P values reflect significance of the experimental values 
compared to vehicle (D). Middle panel: immunoblot of FGFR2 levels in SYT-SSX2-hMSCs 
infected with the indicated FGFR2-shRNAs. 2910 is non-targeting vector and tubulin is 
loading control. Numbers indicate ratio of FGFR2 signal in the cells expressing targeting 
shRNAs relative to non-targeting vector (value 1). Right histogram: dark grey bars are 
average of 833 and 703 cell number over 2910 (value 1). The 2910, 833 and 703 originated 
from the same SYT-SSX2-hMSCs pool (n=3). Light grey bars are the average ratio of NEF-
positive 833 and 703 cells over 2910 NEF-positive (value 1) cells. Error bars indicate 
standard deviation. P values indicate significance of the experimental values with the 
targeting shRNAs compared to non-targeting vector (2910). (B) Decreased NEF expression 
and growth of synovial sarcoma SYO-1 cells after inhibition of FGF signaling. Left image 
panel depicts NEF signal (red) with increasing concentrations of PD173074 in SYO-1 cells. 
Nuclear SYT-SSX2 (green) was visualized with the anti-SSX2 B56 antibody. DMSO was the 
vehicle control. Images were taken at 20X magnification. Middle upper histogram: average 
ratio of NEF-positive cells exposed to DMSO (D) or PD173074 to untreated (U; value 1) 
SYO-1 cells (n=2; over 1000 cells were included in each category). Error bars indicate 
standard deviation. P value reflects significance of the experimental values compared to 
vehicle (D). Middle lower histogram shows growth inhibition of SYO-1 cells with increasing 
concentrations of PD173074 (n=2). Cell growth was estimated using the SRB colorimetric 
assay. Error bars represent standard deviation. P value reflects significance of the 
experimental values compared to vehicle (D). Immunoblot shows FGFR2 levels in shRNA-
treated SYO-1 cells. Tubulin is loading control. Numbers indicate ratio of FGFR2 signal in 
targeting shRNA cells relative to non-targeting vector (2910). Upper right histogram: effect 
of 2910, 833 and 703 FGFR2-shRNAs on NEF expression in SYO-1 cells, relative to NEF-
positive naïve (N; value 1) cells. Error bars represent standard deviation (n=3; 
approximately 1000 cells were included for each category). P value indicates significance 
of the experimental values with the targeting shRNAs compared to non-targeting vector 
(2910). Lower right histogram demonstrates the effect of the 3 FGFR2-shRNAs on SYO-1 
growth using the SRB assay (n=2). Error bars represent standard deviation. P value 
indicates significance of the experimental values with the targeting shRNAs compared to 
non-targeting vector (2910). (C) Effect of SYT-SSX2 siRNA in SYO-1 cells. Left immunoblot: 
SYT-SSX2 levels in INV control and 2 SSX2-targeting RNAs (Si-SSX2A and Si-SSX2B) in 
SYO-1 lysates detected with antibodies B56 (anti-SSX2) and SV11 (anti-SYT). Tubulin is 
loading control. Middle immunoblot: FGFR2 levels in the same lysates. Numbers indicate 
ratio of FGFR2 signal with the targeting Si-SSX2 SiRNAs over control RNA (INV). 
Histogram: effect of SYT-SSX2 siRNA on NEF formation in SYO-1 cells. Numbers indicate 
the average ratio of NEF-positive Si-SSX2A and Si-SSX2B cells to NEF-positive INV control 
cells (value 1). Error bars denote standard deviation (n=3; over 1000 cells were counted for 
each category). P value indicates significance of the experimental values with the 
targeting Si-SSX2 SiRNAs compared to control RNA (INV). Measurements of FGFR2 
depletion by the targeting shRNAs, or by the SYT-SSX2 SiRNAs were performed using the 
Fluorchem 8900 densitometer, and analyzed with the AlphaEase FC software. 
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these events in SYO-1 cells are dependent on SYT-SSX2 expression. We found 
that depletion of SYT-SSX2 in SYO-1 cells with specific siRNAs (Figure 5C, left 
panel) was accompanied by a concomitant decrease in FGFR2 levels (Figure 
5C, lower panels) and a marked decrease in the relative number of NEF-positive 
cells (Figure 5C, histogram). We refrained from measuring the effect of SYT-
SSX2 depletion on SYO-1 growth, as the inherent cell toxicity of RNAi assays 
would interfere with its accuracy.     
In summary, these studies suggest that SYT-SSX2 recruitment to the 
Fgfr2 gene results in the activation of FGF signaling, thereby driving the neural 
phenotype in hMSCs and affecting their growth. This mechanism appears to be 





 The data presented here indicate that the synovial sarcoma oncogene 
SYT-SSX2 reprograms mesenchymal stem/progenitor cells by activating a pro-
neural gene network while disrupting normal differentiation. This is most likely 
due to the recruitment of SYT-SSX2 to an extensive array of neural genes, 
resulting in their activation. This corroborates previous reports in which a neural 
phenotype was observed in SYT-SSX-expressing SS cell lines (Ishibe et al., 
2008). Furthermore, knockdown of SYT-SSX in SS cells led to loss of neuronal 
features (the present study and Naka et al., 2010).  
 The upregulation of several mediators representing the central pathways 
known to modulate stem cell behavior is another striking result. It uncovers a 
propensity of SYT-SSX2 for regulating developmental pathways. This may reflect 
an ability of SYT-SSX2 to create an imbalance in the microenvironment of the 
cancer cell in vivo, furthering malignancy. We have previously reported that SYT-
SSX2 mediates nuclear translocation and activation of -catenin (Pretto et al., 
2006). Consistent with this finding is the upregulation of Wnt ligands in our 
microarray analyses. The crosstalk among Wnt, TGF/BMP, FGF, Hedgehog, 
and Notch, and their impact on tumor cell behavior, are the focus of future 
studies.  
 Our high-throughput analyses identify FGFR2 as a critical signaling node 
in the behavior of SYT-SSX2-expressing cells. Its enhanced signaling by SYT-
SSX2 may explain the accelerated osteoblastogenesis as well as the dominance 
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of the pro-neural gene profile. With MAPK/ERK and PI3K activation, FGFR2 
signaling promotes neurogenesis and skeletogenesis through crosstalk with Wnt, 
Hedgehog, Notch, and BMP signals (Ever and Gaiano, 2005; Chadashvili and 
Peterson, 2006; Maric et al., 2007; Zhao et al., 2008; Miraoui and Marie, 2010). 
Furthermore, the benefit of FGF pathway attenuation to inhibit SS cell growth 
was previously reported (Ishibe et al., 2008) and corroborated by our studies. 
Chemical inhibition of FGFR2 signaling and its depletion with shRNA causes loss 
of neurofilament expression and decreased cell growth in both the SYT-SSX2 
hMSCs and the SS SYO-1 tumor cells. Significantly, upregulation of FGF ligands 
in the myoblast and hMSC microarrays suggests that SYT-SSX2 establishes an 
autocrine FGF signaling loop. If this is the case, identification of FGFR2 as the 
mediator of these signals designates it as a candidate for potential SS tumor 
reversal. Increased FGFR2 activity is already linked to advanced malignant 
phenotypes in endometrial, uterine, ovarian, breast, lung and gastric cancers. 
Strategies designed to target FGFR2 in these cancers (Katoh, 2008; Katoh and 
Katoh, 2009) are ongoing. 
 The deregulation of differentiation in our model systems can also be 
explained by these findings. FGFR2-induced osteoblast maturation (Miraoui and 
Marie, 2010) inhibits adipogenesis in mesenchymal stem cells (Muruganandan et 
al., 2009). Similarly, the stimulation of a neural program by SYT-SSX2 may 
abrogate myogenesis. In C2C12 cells, the two outcomes are mutually exclusive 
(Watanabe et al., 2004). Alternatively, direct silencing of myogenic genes can 
also contribute to this phenotype. The ChIPSeq analysis revealed a putative 
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SYT-SSX2 binding site upstream of the downregulated MyoD gene. Additional 
studies are underway to test this possibility and identify potential recruitment 
factors associated with transcriptional silencing by SYT-SSX2. 
In summary, our studies in mesenchymal stem and progenitor cells 
uncover a function of SYT-SSX2 in differentiation programming, and our 
genome-wide analyses provide a glimpse into the early events of tumor initiation 
by the oncogene. Overall, we believe that the deregulation of differentiation is a 
manifestation of the ability of SYT-SSX2 to target lineage-specific programs. 
FGFR2 was identified as a cardinal player in SYT-SSX2-associated phenotypes, 
but it is likely that additional pathway mediators also contribute to SYT-SSX2-
induced characteristics. Future investigation of other targets identified through 
this method will lead to a better understanding of the interplay among these 
pathways and SS pathology. This combination analysis also provides a powerful 
tool in the discovery of novel therapeutic targets and will be advantageous in 










 Dynamic regulation of chromatin structure allows for DNA-dependent 
processes to be controlled in an epigenetic fashion, or in other words, 
independently of the DNA sequence. Work in recent years has made it 
increasingly clear that gene expression not only depends on the presence of 
sequence-specific transcription factors but also on the structure of the chromatin 
fiber. Moreover, certain post-translational modifications of the core histone 
proteins are known to be associated with specific chromatin states. For example, 
heterochromatin is characterized by the presence of trimethylated histone H3 at 
lysine 9 or 27 (H3K9me3, H3K27me3) and ubiquitylated histone H2A at lysine 
119 (H2AUb) (Bannister and Kouzarides, 2011; Trojer and Reinberg, 2007). In 
general, histone acetylation is associated with euchromatin and reflects 
transcriptional activation (Bannister and Kouzarides, 2011). Gene activity is also 
closely correlated with trimethylation of histone H3 on lysine 4 (H3K4me3) and 
ubiquitylation of histone H2B on lysine 123 (H2BUb) (Bannister and Kouzarides, 
2011; Weake and Workman, 2008). Whether these modifications elicit functional 
changes themselves or whether they are part of a larger mechanism regulating 
chromatin stability that, in turn, controls DNA-dependent processes is a matter of 
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debate (Henikoff and Shilatifard, 2011). In either case, knowing the complement 
of epigenetic markers at a given locus provides valuable information regarding its 
functional status. 
 Indeed, recent evidence suggests that co-regulated gene subsets are 
characterized by common histone modification signatures. New computational 
methods are now considering histone modifications to predict cell-type specific 
transcription factor binding sites more accurately (Wang, 2011; McLeay et al., 
2011). In addition, it has been shown that genes participating in similar functional 
pathways that also display identical expression patterns are marked by the same 
complement of histone modifications in yeast and mouse myoblasts (Natsume-
Kitatani et al., 2011; Asp et al., 2011). Therefore, the combination of markers 
may serve as a signature for transcriptional regulators denoting the coordinated 
expression of these genes. 
 Development is one process during which many genes are coordinately 
regulated within specific cell-types. This is directed by sequence-specific 
transcription factors. For example, MyoD and REST/NRSF are master regulators 
of the myogenic and neurogenic programs, respectively, and these transcription 
factors control the expression of genes important in the differentiation and 
function of their respective lineages (Weintraub et al., 1989; Schoenherr and 
Anderson, 1995). Tissue-specific expression of individual genes may also be 
regulated by enhancers, non-coding DNA elements to which multiple 
transcription factors may bind. These are diverse regulatory elements that 
function independently of distance and orientation relative to their target genes 
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but have some distinguishing characteristics like DNase I hypersensitivity, p300 
binding, and common histone modifications such as mono- and dimethylated 
histone H3 at lysine 4 and acetylated histone H3 at lysines 9, 14, 18, or 27 (Ong 
and Corces, 2011).  
 In the previous chapter, we described the activation of a neural program 
accompanied by the inhibition of the myogenic program in C2C12 myoblasts. 
This was due to the specific targeting of neural genes by the SYT-SSX2 fusion 
protein. Because the translocation product is known to associate with epigenetic 
regulators and that the subsets of genes in euchromatic versus heterchromatic 
regions is cell-type specific, we wanted to determine if there was a signature set 
of epigenetic markers that was associated with SYT-SSX2 recruitment. 
Furthermore, we wanted to ascertain whether a specific set of markers could 




SYT-SSX2 binding is heterogeneous and strongly correlates with histone H3 
lysine 27 trimethylation 
 In the previous chapter, we described a genomewide ChIPSeq experiment 
performed in C2C12 myoblasts expressing the oncogene SYT-SSX2. This 
analysis led to the identification of nearly 53,000 regions (or peaks) bound by the 
SYT-SSX2 complex. In order to generate a global picture of SYT-SSX2 binding 
sites throughout the genome, we performed a sliding window analysis in which 
each chromosome was subdivided into 500kb bins, and the number of SYT-
SSX2 peaks in each bin was tabulated.  
 SYT-SSX2 displays heterogeneous binding among the chromosomes as a 
whole and along each chromosome individually (Figure 6A, Appendix B Figure 
B5). Nearly 20% of the binding sites (9,750) are located on the X chromosome, 
whereas chromosome 3 has 674 binding sites (1.3%) (Table 5). Interestingly, 
areas with high levels of binding are located at chromosome ends, notably on 
chromosomes 2, 4, 11, 15, and X (Figure 6A, Appendix B Figure B5). This trend 
is also seen to a lesser degree on chromosomes 7, 8, 12, and 16-19 (Appendix B 
Figure B5). 
 Binned binding sites appear to cluster loosely into 3 density categories: 
low, medium, and high. Low-density clusters are similar to the cluster centered 
around 5Mb on chromosome 2 and contain bins with <100 peaks (Figure 6A, 
arrowhead). Medium-density clusters contain 1-2 bins with 100-200 peaks  
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surrounded by other bins with less than 100 peaks like the clusters centered at 
28Mb or 74Mb on chromosome 2 (Figure 6A, arrows). The cluster centered at 
179Mb on chromosome 2 (Figure 6A, double arrowhead) is an example of a 
high-density cluster which contains bins with >200 peaks with nearby bins 
containing >100 peaks. These data indicate that SYT-SSX2 recruitment to target 
loci is non-random and displays a preference to specific chromosomal regions. 
 
Table 5. Distribution of SYT-SSX2 peaks per chromosome. 








1 1,651 3.1 11 3,712 7.0 
2 5,311 10.0 12 2,573 4.9 
3 674 1.3 13 1,145 2.2 
4 6,309 11.9 14 1,493 2.8 
5 4,146 7.8 15 3,202 6.0 
6 1,913 3.6 16 798 1.5 
7 1,846 3.5 17 1,842 3.5 
8 2,759 5.2 18 836 1.6 
9 1,466 2.8 19 801 1.5 
10 765 1.4 X 9,750 18.4 
 
 
 Previous reports have shown that SYT-SSX2 interacts with proteins 
involved in transcriptional regulation by epigenetic mechanisms. Therefore, we 
wanted to determine if SYT-SSX2 binding might be associated with specific 
epigenetic markers. Previously published genome-wide datasets for histone 
modifications and RNA polymerase II binding sites (PolII) (Asp et al., 2011) in 
C2C12 myoblasts were compared with our SYT-SSX2 dataset allowing us to 
determine the nature of the epigenetic landscape to which SYT-SSX2 was 
recruited. Positions of histone modification enrichment and protein binding are 
reported as chromosomal positions, thus areas where the datasets intersect can 
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be determined computationally. For our study, we looked for regions that overlap 
≥ 1 nucleotide since SYT-SSX2 interacts with large protein complexes, and a 1-
base overlap suggests close proximity to a given modification. By this method, 
we found quite strikingly that 22,537 SYT-SSX2-occupied regions (42.5%) 
overlapped with H3K27me3 (Table 6 and Figure 6B, left panel), a modification 
associated with Polycomb repressive complexes. This represents approximately 
13% of the total H3K27me3-enriched regions (Table 7) indicating that SYT-SSX2 
is targeted to a subset of Polycomb-regulated genes. Overlap with other histone 
modifications and PolII was not as extensive (Figure 6B, left panel, Tables 6 and 
7). The next highest amount of overlap was seen with H3K4me1 (3,498 peaks, 
6.6%) followed by H3K18Ac (1,961 peaks, 3.7%). This accounts for 1.3% and 
0.99% of the total number of regions marked by H3K4me1 and H3K18Ac, 
respectively (Table 7), indicating that SYT-SSX2 is associated with only a small 
subset of locations labeled by either of these modifications. It has been 
suggested that these marks identify enhancer elements (Ong and Corces, 2011) 




Table 6. Number of SYT-SSX2 peaks that overlap epigenetic markers. 
The number and percent of peaks are relative to the total number of SYT-SSX2 peaks (52,992). 








H3K4me1 3498 6.6 H3K9Ac 595 1.12 
H3K4me2 816 1.54 H3K18Ac 1961 3.70 
H3K4me3 905 1.71 H3K36me3 238 0.45 
H3K27me3 22,537 42.5 H4K12Ac 995 1.88 
PolII 1034 1.95 H2BUb 245 0.46 
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Table 7. Overlap of epigenetic markers with SYT-SSX2. 
The number and percent of peaks are relative to the total number of peaks for a given 
modification. 








H3K4me1 4,118 1.28 H3K9Ac 727 1.12 
H3K4me2 955 1.32 H3K18Ac 2,210 0.99 
H3K4me3 1,118 1.48 H3K36me3 275 0.17 
H3K27me3 27,608 13.1 H4K12Ac 1,155 1.16 
PolII 1,054 2.25 H2BUb 263 0.14 
 
 
The prominence of SYT-SSX2 occupying regions that were previously 
determined to be enriched in H3K27me3 led to the question of where these 
areas were located relative to known genes. It has been shown that PcG 
complexes can mediate both short- and long-range control of gene expression 
(Sparmann and van Lohuizen, 2006; Mateos-Langerak and Cavalli, 2008), thus 
we determined the location of the overlapping regions between SYT-SSX2 and 
H3K27me3 relative to known genes. 3,692 genes could be annotated to SYT-
SSX2/H3K27me3 intersecting areas, and of these, 45.6% of the peaks were 
located within the gene itself (Table 8). Nearly 900 genes had overlapping sites 
from 0-5kb upstream of the TSS, and together with the genes marked by SYT-
SSX2/H3K27me3 regions within the coding sequence, they account for 50% of 
the total SYT-SSX2-Polycomb labeled genes (Table 8). These data strongly 
indicate that SYT-SSX2 interacts with Polycomb complexes that function at 
short-range. Altogether, these data illustrate that SYT-SSX2 may be 
preferentially targeted to specific genomic locations through interaction with 
Polycomb complexes and/or their associated histone modifications. This is 
consistent with previous studies in which SYT-SSX2 was able to associate with 
Polycomb proteins (Barco et al., 2009; Lubieniecka et al., 2008). Moreover, SYT-
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SSX2 may function through the modulation of Polycomb activity via short-range 
interactions. 
 
Table 8. Distribution of SYT-SSX2 peaks overlapping with H3K27me3 with respect to gene 
TSS. 
Regions of SYT-SSX2 binding intersecting with regions of H3K27me3 (≥ 1 nucleotide) were 
annotated to the closest TSS. 3,692 genes were found to be associated with SYT-
SSX2/H3K27me3 in this manner. Percent of genes refers to the number of genes with an SYT-
SSX2/H3K27me3 overlapping region at a given distance over 3,692.  
Distance Number of genes Percent of genes 
In gene 1682 45.6 
0-5 kb 872 23.6 
In-5 kb 1874 50.8 
0-20 kb 1672 45.3 
20-50 kb 1524 41.3 




Differential binding patterns are associated with transcriptional activity 
 SYT-SSX2 can elicit changes in gene expression in target cells through 
direct association with transcriptional regulators, thus we wanted to correlate 
SYT-SSX2 occupancy with gene expression. In the previous chapter, we 
described the binding of SYT-SSX2 peaks with respect to gene transcription start 
sites and found that approximately 10% of the peaks fell within 10kb upstream of 
TSS whereas the majority of peaks are located at distances greater than 50kb 
(Table 1). Through gene expression profiling we were able to associate 
approximately 200 upregulated and 50 downregulated genes with SYT-SSX2 
occupancy within a 10kb window. By including differentially regulated genes with 
binding sites at any distance upstream of the TSS or within the gene body, we 
identified a total of 460 upregulated and 280 downregulated genes associated 
with SYT-SSX2 peaks. These genes were mapped to their relative chromosomal 
location to determine if there was an association between the number of SYT-
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SSX2 peaks and gene activity. As a general trend, negatively regulated genes 
are associated with low-density clusters (Figure 6A) while high-density clusters 
most often correspond to positively regulated genes (Figure 6A). Interestingly, 
there does not appear to be a correlation between the degree of SYT-SSX2 
binding and the number of genes that are either up- or downregulated. On 
chromosome 4, a high-density cluster is centered around 153Mb, however only 2 
genes (1 upregulated and 1 downregulated) are associated with this area (Figure 
6A, box). Conversely, on chromosome 15, a region dense with activated genes 
centered at 102Mb most closely corresponds to a low-medium density cluster 
(Figure 6A, oval). Taken together, these data indicate that SYT-SSX2 binding 
correlates with alterations in gene activity; however, not all binding sites are 
associated with changes in gene expression suggesting that SYT-SSX2 may 
have additional functions in the nucleus. 
 We narrowed our focus to study differentially regulated genes locally in 
order to determine if gene activation versus repression could be distinguished by 
SYT-SSX2 binding patterns. Interestingly, the distribution of SYT-SSX2 binding 
sites upstream of the TSS was markedly different depending on whether a gene 
was positively or negatively regulated by oncogene expression. Overall, more 
than half of the upregulated genes bound by SYT-SSX2 (53.9%) have at least 1 
peak within a window from 0-20kb upstream of the TSS. This number decreases 
with increasing distance (Figure 7, top panel). In contrast, 21.4% of the genes 
that are downregulated and bound by SYT-SSX2 have peaks within a 0-20kb 
window upstream of the TSS. This percentage increases with increasing  
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distance, peaks from 50-100kb then decreases at distances between 100-150kb 
and 150-200kb (Figure 7, top panel). These data suggest that SYT-SSX2-
associated transcriptional activation is correlated with binding at close range 
whereas transcriptional repression associates with binding at farther distances.  
 
Binding patterns associated with differentially regulated genes 
 Recently, it has been shown that genes within specific functional 
categories can be distinguished by the pattern of histone modifications 
surrounding them. This suggests that genes within a particular pathway have a 
specific epigenetic signature that allows them to be differentially recognized by 
activating and/or repressing factors. In this way, the cell can co-regulate the 
expression of genes involved in a given process (Asp et al., 2011; Natsume-
Kitatani et al., 2011). We have hypothesized that SYT-SSX2 targets genes 
through an epigenetic mechanism. To further delineate the SYT-SSX2 binding 
pattern, overlap of SYT-SSX2 peaks with histone modifications at differentially 
regulated genes was determined. Seventy-two percent (72%) of the upregulated 
genes and 43.6% of the downregulated genes bound by SYT-SSX2 have 
associated peaks that overlap with H3K27me3 (Figure 7, bottom panel) 
corroborating previous reports that the fusion protein is targeted to Polycomb-
regulated genes. Surprisingly, 43.6% of the upregulated genes and 33.6% of the 
downregulated genes have SYT-SSX2 peaks that overlap with H3K4me1. This is 
significant considering that the overlap with H3K4me1 occurs with only 6.6% of 
the total SYT-SSX2 peaks overall. Since this modification labels enhancer 
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elements (Ong and Corces, 2011), the association of SYT-SSX2 with these sites 
as well as Polycomb target sites suggests that SYT-SSX2 may affect 
transcription by modulating both enhancer and Polycomb function.  
 Next we wanted to discover if the overlap of SYT-SSX2 binding exhibited 
any patterns that would allow us to distinguish differentially regulated genes. As a 
first step, we tabulated the number SYT-SSX2 peaks for each gene within a 
particular expression category (positively or negatively regulated) that overlapped 
with histone modifications, PolII binding, and DNA methylation in 5kb windows up 
to 50kb upstream of TSS and within the gene. We limited our analyses to this 
distance because of the association of SYT-SSX2 with Polycomb-marked 
regions at close-range to gene TSS and because of the difficulty in definitively 
assigning functional significance to binding sites at farther distances. For this 
analysis we also only characterized genes that had SYT-SSX2 binding sites that 
overlapped with at least 1 epigenetic marker and identified 314 upregulated and 
110 downregulated genes by this criterion. Of these upregulated genes, 50% had 
overlapping sites between the fusion protein and H3K27me3 (Table 9). This 
percentage decreases with increasing distance consistent with the trend 
described above with respect to all genes with SYT-SSX2/H3K27me3 
intersecting regions. Also consistent with trends described above, the second 
most abundant overlap occurred between SYT-SSX2 and H3K4me1 within the 
gene body. Association between SYT-SSX2 and other histone modifications, 
particularly those related to transcriptional activation (but not elongation) was 
also seen within gene bodies, although to a much lesser extent than either 
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H3K27me3 or H3K4me1 (Table 9). In general, the number of genes in which 
SYT-SSX2 associated with these other modifications decreased with increasing 
distance, although there are a few exceptions.  
 
Table 9. Distribution of SYT-SSX2-overlapping epigenetic markers with respect to 
upregulated genes. 
Percentages are relative to the total number of upregulated genes with SYT-SSX2 peaks that 
overlap any epigenetic marker from 0-50kb upstream of the TSS and including the gene body 
(total = 314). Distances are measured in kilobases. 
















DNA me 9.55 4.46 0.32 0.96 0.32 0 0 0.64 0.32 0.64 0.64 
H3K4me1 18.8 5.10 2.23 5.41 5.73 2.55 6.37 3.82 4.46 4.46 5.73 
H3K4me2 8.28 5.10 0.32 1.27 0.64 0.64 0.96 0.32 0.96 0.96 0.64 
H3K4me3 8.60 4.14 0.64 1.27 0.32 0.64 0.64 0.32 0.64 1.27 0.96 
H3K27me3 50.0 31.2 29.3 25.7 23.9 24.5 23.6 21.3 21.3 22.0 19.4 
H3K9Ac 5.10 0.64 0.32 0.64 0 0.32 0.96 0.32 0.64 1.91 0.64 
H3K18Ac 9.24 2.23 1.91 2.23 2.55 2.55 2.55 2.23 3.82 4.78 3.50 
H3K36me3 2.87 0 0 0.32 0.64 0.32 0.32 0.96 0 0.96 0.32 
H4K12Ac 7.32 1.27 0.64 1.59 1.27 0.96 0.64 1.27 1.59 1.91 0.96 
H2BUb 1.27 0 0 0.32 0.32 0.64 0.32 0.64 0 0.32 0 
PolII 10.2 3.18 1.59 1.91 1.27 1.27 1.27 1.59 1.27 2.23 2.55 
 
 
Table 10. Distribution of SYT-SSX2-overlapping epigenetic markers with respect to 
downregulated genes. 
Percentages are relative to the total number of downregulated genes with SYT-SSX2 peaks that 
overlap any epigenetic marker from 0-50kb upstream of the TSS and including the gene body 
(total = 110). Distances are measured in kilobases. 
















DNA me 7.27 4.55 0.91 0.91 0 0.91 0.91 0 0 0.91 2.73 
H3K4me1 23.6 8.18 9.09 8.18 5.45 3.64 8.18 5.45 3.64 8.18 1.82 
H3K4me2 17.3 10.0 3.64 1.82 1.82 3.64 3.64 0 0 4.55 2.73 
H3K4me3 17.3 10.9 2.73 3.64 1.82 4.55 2.73 0.91 0.91 3.64 6.64 
H3K27me3 22.7 3.64 10.0 7.27 7.27 7.27 12.7 8.18 11.8 15.5 16.4 
H3K9Ac 14.6 9.09 4.55 3.64 2.73 1.82 1.82 0 0 2.73 1.82 
H3K18Ac 17.3 3.64 7.27 6.36 4.55 2.73 3.64 0 4.55 3.64 3.64 
H3K36me3 8.18 0.91 1.82 1.82 0.91 2.73 0.91 0.91 1.82 0 0 
H4K12Ac 12.7 9.09 3.64 7.27 1.82 3.64 1.82 0 0 3.64 2.73 
H2BUb 7.27 0 1.82 0.91 0 1.82 0 0.91 1.82 0 0.91 
PolII 18.2 10.0 3.64 0.91 4.55 2.73 1.82 2.73 0.91 2.73 4.55 
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Of the negatively regulated genes, the highest levels of overlap were also 
seen in the gene body and occurred with H3K4me1 and H3K27me3 (Table 10). 
For H3K4me1, the number of genes with intersection of this mark with SYT-
SSX2 occupancy generally decreases with increasing distance upstream of the 
TSS; however, from 25-30kb and 40-45kb the number of genes with SYT-
SSX2/H3K4me1 regions was increased relative to the surrounding windows 
(Table 10). For H3K27me3, a slightly different pattern is seen. The number of 
genes with SYT-SSX2/H3K27me3 sites decreases dramatically from 0-5kb but 
increases with increasing distance upstream of the TSS (Table 10).  
With downregulated genes, SYT-SSX2 also appears to associate with 
modifications related to active transcription. Regions enriched in H3K4me2, 
H3K4me3, H3K9Ac, H3K18Ac, H4K12Ac, and PolII occupancy overlap with SYT-
SSX2 binding sites in over 10% of the downregulated genes, and markers 
associated with transcriptional elongation (H3K36me3 and H2BUb) overlap with 
SYT-SSX2 sites in more than 5% of the downregulated genes (compared with 
less than 3% of the upregulated genes). In summary, SYT-SSX2 associates with 
epigenetic markers, particularly H3K27me3 and H3K4me1. Most of the 
upregulated genes in this analysis are marked by H3K27me3, and SYT-SSX2 
appears to bind close to the TSS. In contrast, SYT-SSX2 occupies H3K4me1- or 
H3K27me3-enriched regions in a similar percentage of downregulated genes and 
also associates with more markers of transcriptional activation and elongation.  
In order to determine higher order relationships among the histone 
modifications themselves and gene expression, and using the criterion that 
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genes were included if they contained a binding site for SYT-SSX2 that 
overlapped with at least 1 epigenetic marker, hierarchical clustering was 
performed on the differentially regulated genes. To do so, the degree of overlap 
between SYT-SSX2 and a given modification was calculated as a ratio of bases 
covered per 5kb bin upstream of the TSS or the ratio of bases covered in the 
gene body over the total number of bases in the coding sequence. This data 
generated a signature of modifications by distance for each gene and was used 
in hierarchical clustering analyses.  
Analysis of the upregulated genes corroborated earlier results and 
identified H3K27me3 as the predominant modification associated with SYT-SSX2 
binding and gene expression (Figure 8, top panel). The location and extent of 
H3K27me3 was variable across all genes, but there were 2 sub-clusters in which 
SYT-SSX2/H3K27me3 intersecting sites were located within the entire range of 
distances that we analyzed. The first of those sub-clusters is highlighted in Figure 
8 (top panel). It has been reported previously that genes densely covered by 
H3K27me3 were involved in the differentiation and development of alternate 
lineage pathways, thus we wanted to determine the function of the genes within 
this sub-cluster. Based on our previous analysis (Chapter 3), we found that 50% 
of these genes are involved in neural development and function. To summarize, 
SYT-SSX2 occupies regions within and upstream of upregulated genes that are 
enriched in H3K27me3. Functionally, these genes can be subdivided based on 
the extent of SYT-SSX2/H3K27me3 intersection and are in line with our previous 
observation of the increased expression of neural characteristics and genes. 
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Similar hierarchical clustering was performed on the downregulated 
genes. This analysis led to the identification of 2 clusters of genes with 
differential signatures. The first is characterized by SYT-SSX2/H3K27me3 
overlap from 0-10kb and 20-50kb upstream of gene TSS, whereas the second 
cluster is marked by the overlap of SYT-SSX2 with histone modifications related 
to transcriptional activation at close ranges (Figure 8, bottom panel). 
Interestingly, these two signatures appear to be mutually exclusive. SYT-
SSX2/H3K27me3 overlaps are minimal or absent in the genes marked by close-
range SYT-SSX2 intersection with activating modifications and vice versa (Figure 
8, bottom panel). Additionally, unlike the upregulated genes, which were 
functionally related based on their clustering, the genes within these clusters 
were not clearly associated with a particular pathway or program. Together, 
these data suggest that SYT-SSX2-mediated downregulation of gene expression 
occurs through different mechanisms, one dependent on recruitment by 
Polycomb and the other independent of Polycomb. 





 Genome-wide analysis of SYT-SSX2 distribution and subsequent 
alterations in gene expression revealed that both its binding and functional 
consequences are non-random events. Heterogeneous binding of the fusion 
protein was found across all chromosomes in terms of the number of peaks per 
chromosome and density at specific loci on individual chromosomes. 
Comparison of these binding sites with epigenetic markers further supported the 
preference of SYT-SSX2 for regions bound by Polycomb complexes and 
established its association with a subset of Polycomb-regulated loci. In addition, 
a small subpopulation of the genes bound by SYT-SSX2 displayed alterations in 
expression. These genes were typified by certain epigenetic attributes: 
upregulated genes were characterized by the predominant association of SYT-
SSX2 with regions enriched in H3K27me3, whereas downregulated genes could 
be subdivided into at least 2 categories distinguished by occupation of the fusion 
protein in regions displaying either H3K27me3 enrichment at short- and long-
ranges or the presence of modifications associated with transcriptional activation 
within the gene body or near the TSS. 
 The data described here provide a foundation for uncovering the 
mechanism of SYT-SSX2 recruitment. The preeminent association of SYT-SSX2 
with H3K27me3 supports previous reports of interaction with Polycomb 
complexes (Thaete et al., 1999; dos Santos et al., 2000; Barco et al., 2009) and 
indicates that the fusion protein does not simply target to regions of open 
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chromatin by default. Furthermore, because it occupies only a subset of 
Polycomb loci, the presence of additional targeting factors, genetic or epigenetic, 
is also likely. One possibility is PRC1. The H3K27me3 modification is catalyzed 
by PRC2, and it is known that PRC1 and PRC2 do not occupy completely 
identical sets of genes within a given cell type (Ku et al., 2008; Asp et al., 2011). 
Direct interaction of the fusion protein has only been seen with the PRC1 
component Ring1b (Barco et al., 2009), thus it follows that SYT-SSX2 will not 
associate with all H3K27me3-labeled regions. Furthermore, PRC1 may also be 
recruited to chromatin independently of PRC2 (Kerppola, 2009). Recruitment of 
SYT-SSX2 by PRC1 could then explain at least some of the other binding sites 
that are not enriched for H3K27me3. Therefore, it would be interesting to 
determine the degree of overlap between SYT-SSX2 ChIPSeq and genome-wide 
binding patterns of PRC1 in C2C12 cells. 
 Our genome-wide analyses revealed that SYT-SSX2 is targeted to over 
3,000 genes, yet alterations in expression are noted for, at most, 740 of these 
targets. This may be due to experimental errors from the high-throughput 
analyses in the forms of false-positive SYT-SSX2 peaks or false-negative 
changes in gene expression. Alternatively, it is not unprecedented that the 
number of binding sites for a particular factor is far greater than the number of 
genes that are differentially expressed when that factor is induced. MyoD was 
found to bind to the promoter region of 3,719 genes, yet only 384 of these genes 
were upregulated during myogenesis (Cao Y et al, 2010). Similarly, the PAX3-
FKHR fusion associated with rhabdomyosarcoma bound to 1,072 genes, 
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however only 95 and 24 of these genes were found to be differentially regulated 
in PAX3-FKHR-bearing tumor cells and cell lines, respectively (Cao L et al., 
2010). These data also suggest that additional signals may be required in order 
to produce functional outcomes after binding to target loci. In support of this 
notion, a recent report studying genome-wide binding of p53 indicated that 
differential gene expression upon treatment with etoposide versus actinomycin D 
was due to altered p53 phosphorylation rather than changes in binding sites 
(Smeenk et al., 2011). In the same way, alterations in gene expression by SYT-
SSX2 may result from subsequent signaling events. 
 We were able to identify differential signatures for upregulated versus 
downregulated genes based on SYT-SSX2 binding site distance as well as the 
complement of epigenetic markers underlying SYT-SSX2-occupied regions. 
There is an apparent difference based on distance between positively- and 
negatively-regulated genes marked by H3K27me3. Most genes with increased 
expression have SYT-SSX2 binding sites within the gene body or near the TSS 
while greater numbers of genes with decreased expression are occupied at a 
distance. This dissimilarity may reflect alternate mechanisms of PRC-mediated 
silencing. For example, it has been reported that the structure of PRC1 may differ 
when it is proximal to the TSS versus when it is bound distally; functionally, this 
results in opposite consequences on gene expression after depletion of PRC1 
components (Ren and Kerppola, 2011). Therefore, PRC1 dysfunction caused by 
SYT-SSX2 could result in opposite effects. Another explanation may involve the 
ability of SYT-SSX2 to interact with Brg1. In ES cells, Brg1 tunes expression of 
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Polycomb target genes resulting in either activation or enhanced silencing, and 
so may augment repression rather than antagonize it (Ho et al., 2011).  
 In addition, a second subcluster of downregulated genes was 
characterized by the presence of histone modifications associated with active 
transcription within the gene or proximal (0-5kb) to the TSS. Together with the 
fact that close-range binding by SYT-SSX2 at Polycomb-regulated genes results 
in gene activation, these data indicate that proximal binding by the fusion protein 
functions to antagonize the transcriptional status of target genes. Moreover, 
previous work has indicated that these are both consequences of aberrant 
Polycomb function since SYT-SSX2 has been shown both to antagonize and to 
initiate Polycomb silencing (Barco et al., 2009; Lubieniecka et al., 2008). In this 
way, SYT-SSX2 may act as a switch protein that generally opposes the gene 
expression profile of the cell.  
 The specificity for the upregulation of neural genes can be explained by a 
number of different mechanisms. The first involves the endogenous expression 
of certain factors that makes a particular outcome more likely in one cell versus a 
different type. It is hypothesized that expression is the result of the balance 
between Polycomb and Trithorax activity at a given gene, and some cell types 
may possess additional regulators that can affect gene expression once that 
balance has been perturbed (Schwartz and Pirotta, 2008; Schwartz et al., 2010). 
Interestingly, aberrant expression of E-cadherin results from the co-expression of 
SYT-SSX with the either of the tissue-specific transcriptional repressors Snail or 
Slug suggesting interaction with repressor molecules directs gene activation by 
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the fusion (Saito et al., 2006). C2C12 cells may then express certain factors that 
could guide the expression of neural genes. One potential factor is the 
REST/NRSF transcriptional repressor that silences neural genes in alternate 
lineages. Inhibition of its activity leads to neurogenesis in C2C12 cells so 
misexpression of its target genes by SYT-SSX2 may result in the ectopic neural 
program seen in these cells (Watanabe et al., 2004).  
 An alternate mechanism may involve the activation of tissue-specific 
enhancer elements. In ES cells, enhancers that control the expression of inactive 
genes involved in differentiation of multiple lineages are labeled by H3K27me3 
and H3K4me1. When these elements become active K27 becomes acetylated, a 
modification that can be catalyzed by p300 (Rada-Iglesias et al., 2010; Tie et al., 
2009). Recruitment of SYT-SSX2 to these elements by interactions with 
Polycomb may lead to increased acetylation of K27 by p300 resulting in their 
activation and subsequent perturbations in the balance between silencing and 
expression. 
 These data allow us to propose a model of recruitment and regulation of 
target gene expression by SYT-SSX2. In the case of upregulated genes, the 
fusion protein is recruited by interactions with PRC1, and gene activity is 
determined by the presence of lineage-specific transcription factors or the 
activation of specific enhancer elements (Figure 9A). For downregulated genes, 
SYT-SSX2 may be recruited by PRC1 or PRC2 at a distance from target 
promoters (Figure 9B, top) or directly targeted to activated genes (Figure 9B, 
bottom). Recruitment may occur through interactions with the modified histones 
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themselves, the complexes that catalyze those modifications, or additional 
proteins like sequence-specific transcription factors. The presence of other 












 The Polycomb proteins are important regulators of gene expression in 
development as well as cancer, and much attention has focused on the 
mechanism through which these proteins regulate differentiation and contribute 
to tumorigenesis. One aspect of Polycomb function that has not been addressed 
extensively is how the activity of these proteins is regulated. PRC1 is considered 
to be the main controller of gene expression by Polycomb proteins, and the most 
detectable function that it performs is the ubiquitylation of histone H2A (Simon 
and Kingston, 2009). This is mediated by the Ring1b protein and facilitated by 
Bmi1, and accordingly, a few studies have concentrated on the regulation of 
these proteins. 
 Bmi1 protein levels are regulated by proteasomal degradation (Ben-
Saadon et al., 2006), and its association with chromatin depends on 
phosphorylation which is modulated by cell cycle progression, mitogen 
stimulation, or induction of cellular stress (Voncken et al., 1999; Voncken et al., 
2005). Like Bmi1, Ring1b undergoes phosphorylation. This is catalyzed by p38 
MAPK and ERK1/2, and this modification is associated with changes in protein 
expression downstream of Ring1b (Rao et al., 2009). Ring1b activity is also 
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controlled by its auto-ubiquitylation as well as an association with Mel18, a Bmi1 
homolog (Ben-Saadon et al., 2006; Elderkin et al., 2007). 
 Previous work in our lab revealed that SYT-SSX2 expression in human 
osteosarcoma cells (U2OS) causes loss of Bmi1 protein levels due to its 
increased degradation (Barco et al., 2009). This results in decreased association 
with its functional partner, Ring1b, and global loss of histone H2A ubiquitylation. 
These alterations are also associated with increased expression of putative 
Polycomb target genes (Barco et al., 2009). These data indicate that SYT-SSX2 
functions, in part, by abrogating PRC1 activity resulting in the erroneous 
activation of Polycomb-silenced genes. Because the deregulation of Polycomb 
activity seems to be the heart of its function, we wanted to determine the 




Bmi1 is phosphorylated in response to various stimuli 
 Our previous studies in U2OS cells indicate that enhanced degradation of 
Bmi1 is the mechanism through which SYT-SSX2 causes transcriptional 
deregulation of Polycomb target genes. To confirm this hypothesis, we 
determined Bmi1 protein levels in C2C12 cells after transduction with oncogene-
containing expression vectors. In some experiments, we were able to detect a 
decrease in the amount of Bmi1 protein in SYT-SSX2-expressing cells compared 
to vector controls (data not shown); however, in the majority of experiments this 
decrease was not seen, and we noted a slight shift in the mobility of Bmi1 instead 
(Figure 10A). The slower migration of Bmi1 in the presence of SYT-SSX2 
suggests that Bmi1 is post-translationally modified in C2C12 cells expressing the 
oncogene. 
 Firstly, because we could recapitulate the findings of our previous study, 
albeit with less reproducibility than the U2OS system, and secondly, because we 
also saw that SYT-SSX2 led to the accumulation of a slower migrating form of 
Bmi1 without a decrease in total protein levels, we hypothesized that the 
modified Bmi1 may be an intermediate in its degradation pathway. Differences 
between U2OS and C2C12 cells in terms of other regulators may account for the 
disparity between outcomes, nevertheless, we suspect that similar mechanisms 
are at work in both cell types. It has been reported that Bmi1 is subject to 




therefore, to determine if Bmi1 protein levels could be enhanced through 
proteasome inhibition, we treated C2C12 cells with ALLN or MG132. 
Interestingly, treatment with both inhibitors led to a decrease in Bmi1 mobility 
similar to what was seen in SYT-SSX2-expressing cells (Figure 10B).  
 The small shift in Bmi1 migration was indicative of the addition of a small 
modification, like phosphorylation, so in order to test whether Bmi1 was 
phosphorylated as a result of proteasome inhibition, we immunoprecipitated 
exogenously-expressed 2PY-tagged Bmi1 from C2C12 cells that were treated 
with MG132 then subjected the samples to a phosphatase assay. Incubation of 
the precipitated complexes from vehicle- and MG132-treated cells with -
phosphatase led to a collapse in the 2PY-Bmi1 band compared to complexes 
with no -phosphatase (Figure 10C) indicating that Bmi1 was phosphorylated in 
both conditions. The inclusion of phosphatase inhibitors in the reaction mixture 
prevented the change in mobility further supporting this finding (Figure 10C). 
Treatment with MG132 led to a slight increase in the height of the 2PY-Bmi1 
band suggesting either a higher amount of phosphorylated species or a higher 
degree of phosphorylation in these samples. Together these data indicate that 
2PY-Bmi1 is phosphorylated under normal conditions. These modified species 
accumulate under conditions of proteasome inhibition and are an intermediate in 
the proteasomal degradation pathway. 
 In experiments where we observed SYT-SSX2-associated decrease in 
Bmi1 signal, proteasome inhibition failed to prevent this loss (data not shown), 
and instead resulted in the increased phosphorylation of Bmi1 as we have 
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described. Because SYT-SSX2 interacts with additional protein complexes 
involved in the epigenetic regulation of transcription, we wanted to determine 
whether the activity of other epigenetic modifiers was required for Bmi1 
regulation. Treatment of C2C12 cells with either curcumin (p300 inhibitor) or 
trichostatin A (HDAC inhibitor) also led to a change in mobility of Bmi1 (Figure 
10B). This indicates that alterations in the activity of epigenetic regulators that 
cooperate with or antagonize Polycomb repression result in modification of Bmi1. 
Interestingly, acute inhibition of tyrosine phosphatases also led to the 
accumulation of the lower mobility Bmi1 species (Figure 10B). Therefore, in 
general, it appears that cellular stress can cause the phosphorylation of Bmi1. 
This is in agreement with previous studies showing that Bmi1 becomes 
phosphorylated under stressed conditions like growth factor deprivation 
(Voncken et al., 2004). These data suggest that Bmi1 may act as a node through 
which various signaling networks may converge. More studies are required to 
understand the nature of Bmi1 regulation through phosphorylation as well as the 
functional consequences of this modification. 
 
Antagonism of Polycomb repression by SYT-SSX2 
 In previous work, we show that SYT-SSX2-mediated antagonism of 
Polycomb repression requires the C-terminal end of SSX2 because of its 
targeting function (Barco et al., 2009). Reports by other groups indicate the 
importance of the N-terminus in transformation (Nagai et al., 2001); however the 
molecular basis for this requirement is unclear. To begin define the mechanistic 
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details of Polycomb antagonism by SYT-SSX2, we made N-terminal deletion 
mutants of the fusion lacking the first 20 (NΔ20) and 40 (NΔ40) amino acids of 
the SYT component and determined the expression of SYT-SSX2 target genes 
that we previously validated in C2C12 cells (Chapter 3, Figure 2). Deletion of the 
N-terminus of SYT-SSX2 led to a graded decrease in the expression of Ngfr such 
that the larger N-terminal deletion restored Ngfr transcript levels to basal. This is 
in contrast to Dll1 and Igf2 which are increased in cells expressing the NΔ20 
mutant and either return to basal levels (Dll1) or a level nearly equivalent with 
full-length SYT-SSX2 (Igf2) (Figure 11A). These differential effects are rather 
confounding, so as a first step to understand the effect of N-terminal deletion on 
transcription, we decided to determine if these mutants retained their ability to 
bind to known SYT-SSX interactors. In preliminary studies, we tested the ability 
of SYT-SSX2 and its N-terminal mutants to associate with Brg1 by 
immunoprecipitation. SYT-SSX2 could co-precipitate Brg1, and this ability to bind 
Brg1 falls below basal levels in the NΔ20 mutant and is lost in the NΔ40 mutant 
(Figure 11C, top left panel). These data indicate that the ability to bind Brg1 may 
not be necessary for activation by SYT-SSX2 in all cases. Further experiments 
are required for the validation of these findings. 
 Our previous studies focused on the global regulation of Bmi1 and 
Polycomb by SYT-SSX2 (Barco et al., 2009), but the present data suggests that 
while global changes can be detected, the mechanism of how these changes 
occur are more likely to be discovered by studies of specific target genes. To 




decided to study the Ngfr gene. We were able to validate Polycomb-mediated 
silencing of Ngfr in C2C12 cells (Figure 11B). By chromatin immunprecipitation 
(ChIP) experiments, we detected the presence of Polycomb-associated histone 
modifications (H3K27me3 and H2AUb) and members of the PRC1 complex 
(Bmi1 and Ring1b) at the Ngfr promoter region in control cells (Figure 11B). 
When SYT-SSX2 was expressed, the levels of H3K27me3, H2AUb, and Bmi1 at 
the Ngfr gene were decreased indicating loss of Polycomb-mediated silencing. In 
addition, we observed lower association of HDAC1 with the Ngfr gene (Figure 
11B). Conversely, ChIP experiments to detect markers of transcriptional 
activation (H3K18Ac, H3K14Ac, and H3K4me3) revealed an increase in these 
modifications in cells expressing SYT-SSX2. To validate that Ngfr is targeted by 
the oncogene, we were also able to demonstrate its presence by ChIP. 
Interestingly, the signal in the Ring1b ChIP increases in the presence of SYT-
SSX2. This phenomenon was reproduced in multiple experiments; however, we 
have not been able to determine the mechanism by which this occurs. 
Altogether, we show that the Ngfr gene is directly targeted by the SYT-SSX2 
oncoprotein and that its expression is associated with increased expression as 
well as alterations in the configuration of the promoter region. Repressive 
proteins and histone marks are lost, while activating marks are gained. Additional 
studies are required in order to understand the interplay of SYT-SSX2 and its 




Inhibition of Ring1b function by SYT-SSX2 
 In U2OS cells, loss of Bmi1 protein as a consequence of SYT-SSX2 
expression results in decreased complex formation with Ring1b. This, in turn, 
was posited to be the cause of the global loss of histone H2A ubiquitylation since 
Bmi1 is known to enhance Ring1b E3-ligase activity (Barco et al., 2009; Cao et 
al., 2005). To understand the effects that SYT-SSX2 may have on Ring1b-Bmi1 
activity, we performed in vitro ubiquitylation studies with recombinant Ring1b and 
Bmi1 purified from bacteria in the presence of immunoprecipitated SYT-SSX2. 
Ring1b has been reported to possess auto-ubiquitylation activity which is 
mitigated by the presence of Bmi1, and this could be seen in our assays (Figure 
12, top panel, top arrow). In the presence of control IP, auto-ubiquitylation of 
Ring1b increased; however, when incubated with SYT-SSX2 IP, the amount of 
ubiquitylated Ring1b decreased relative to the control IP (Figure 12, top panel). 
Furthermore, the amount of total ubiquitylation was decreased in reactions 
containing SYT-SSX2 IP (Figure 12, bottom panel). This inhibition was especially 
decreased in reactions containing only Ring1b. Investigations to confirm this 
finding are required, but these data imply that SYT-SSX2 and/or its associated 
proteins could either inhibit Ring1b activity or recruit an enzyme with 







The experiments described here provide a foundation for future studies to 
elucidate the molecular mechanism of SYT-SSX2 antagonism of Polycomb-
mediated gene silencing. Bmi1 is phosphorylated in response to a number of 
different stimuli, including SYT-SSX2 expression. Phosphorylation of Bmi1 
correlates with its dissociation from chromatin during the cell cycle (Voncken et 
al., 2004); therefore, this modification may explain how Bmi1 is lost from the Ngfr 
promoter. The fact that Bmi1 is phosphorylated after inhibition of HAT and HDAC 
activity suggests that changes in the epigenetic environment in general may also 
cause this event. Knock-down of Suz12 in C2C12 cells results in the re-
distribution of Bmi1 such that the level of Bmi1 bound at genes where PRC1 is 
already resident increases without an overall change in protein level (Asp et al., 
2011). Although it is hypothesized that this guards against the inappropriate 
expression of lineage-specific genes (Asp et al., 2011), the relocation of Bmi1 
may be a more general mechanism that the cell (and perhaps a stem and 
progenitor cells in particular) uses to control the accessibility of certain subsets of 
genes when challenged with a given insult or signal. In consequence, signaling to 
Bmi1 may be one way that various pathways can regulate the expression of 
Polycomb target genes.  
The initial studies we described here using the N-terminal SYT-SSX2 
mutants and the profile of epigenetic markers at the Ngfr promoter provide a 
background for understanding the mechanism of SYT-SSX2 function. We show 
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that Ngfr is a Polycomb target in C2C12 cells and that its repression is reversed 
by SYT-SSX2. Our data also indicate that Brg1 binding may not be critical for 
Ngfr expression; however, its ability to associate with SYT-SSX2 correlates 
strongly with activation of this gene. Thus, Brg1 activity may be required for this 
process, but recruitment by other mechanisms, like histone acetylation, may 
compensate for the inability to associate with SYT-SSX2. Surprisingly, we also 
detected differences in expression among the genes we tested in their 
requirement for the N-terminal 20 amino acids of SYT-SSX2. This may reflect 
differences in the mechanism of regulation at these particular genes. From our 
ChIP and ChIPSeq data (Chapters 3 and 4), SYT-SSX2 binds in close proximity 
to the TSS of Ngfr but not Dll1 or Igf2. This suggests that increased expression of 
these genes may be indirect or due to long-range interactions that are still poorly 
understood.  
The change in histone modifications at the Ngfr promoter occurs as 
expected for a switch from the silenced to an active state. How SYT-SSX2 
mediates these changes remains to be clarified. Histone acetylation is likely due 
to interaction of SYT-SSX2 with p300, and p300 activity may also directly inhibit 
H3K27me3 through acetylation of the same residue (Eid et al., 2000; Tie et al., 
2009). Lysine 27 acetylation in Drosophila requires Trx activity suggesting that 
recruitment of MLL occurs prior to p300 catalytic function. Furthermore, removal 
of the H3K27me3 mark necessarily precedes acetylation and requires the activity 
of a demethylase like UTX or JMJD3 (Lee et al., 2007; Agger et al., 2007). 
Additional studies regarding the sequence of events that is orchestrated by SYT-
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SSX2 at the Ngfr promoter and the identification of novel binding partners will 
contribute further insight into this mechanism. 
Our preliminary data from in vitro ubiquitylation assays indicate the 
inhibition of Ring1b ligase activity or a deubiquitylation activity recruited by SYT-
SSX2 and/or its associated proteins. Thus far we have focused our studies on 
the dynamics of Bmi1 as changes to this protein have been the most visible, and 
we hypothesize that the loss of Bmi1 from PRC1 leads to the derepression of 
Polycomb silencing. Indeed, our ChIP studies at the Ngfr gene indicate that 
Ring1b is retained at the promoter, so we conjecture that the loss of its partner 
protein caused the decrease in H2AUb making transcription permissible. In light 
of the present data, we must now consider the possibility that SYT-SSX2, either 
on its own or by the recruitment of other proteins, actively opposes Ring1b 
function in addition to any effects on Bmi1. A histone H2A deubiquitylase that 
opposes PRC1 has been identified in flies and is homologous to the mammalian 
BAP1 (Scheuermann et al., 2010). In addition, USP7 is able to deubiquitylate 
Ring1b and thus deactivate it (de Bie et al., 2010). It will be interesting to 
determine if SYT-SSX2 can interact with either of these proteins or others with 
similar functions. 
In summary, the derepression of Polycomb target genes by SYT-SSX2 
may take place through both passive and active mechanisms. Understanding 
how this is facilitated by the fusion protein may highlight possible avenues for 





DISCUSSION AND FUTURE DIRECTIONS 
 
Cellular reprogramming by SYT-SSX2 
 
 Taken as a whole, the data presented in this study support cellular 
reprogramming as the mechanism by which SYT-SSX2 induces transformation. 
The remarkable number of neural and developmental genes shared by the 
myoblasts and the hMSCs showcases the dominant programming effect of SYT-
SSX2. Imposing a lineage commitment on stem/progenitor cells appears to be a 
recurrent feature of sarcoma-associated translocations (Mackall et al., 2004). 
One prominent example is PAX3-FKHR, the rhabdomyosarcoma fusion product 
that drives NIH3T3 fibroblasts into a myogenic program (Khan et al., 1999). It is 
thought to induce tumorigenesis through stimulation of lineage commitment and 
simultaneous prevention of terminal differentiation (Charytonowicz et al., 2009). 
Whether SYT-SSX2 acts in a similar manner remains to be seen. Regardless, 
the dominant effect on cellular identity is postulated to be a part of oncogenesis 
initiation by sarcoma-associated translocations and a necessary step toward 
malignant transformation (Mackall et al., 2004). 
 These observations allow us to speculate on the cell-of-origin for this 
malignancy. The capacity of SS cells to be differentiated into mesenchymal and 
neural cell types (Naka et al, 2010; Ishibe et al, 2008) implies that the disease 
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originates in multipotent cells from either of these lineages. Our data indicate that 
the neural features are caused primarily by SYT-SSX2 itself, irrespective of 
cellular context, so the target cell may not necessarily be of neural origin. 
Expression of SYT-SSX2 in multiple lineages in mice recapitulates human 
synovial sarcoma in all cases, attesting to the dominant program established by 
the oncogene and its capacity to transform different cell types (Haldar et al., 
2009). Additionally, expression of SYT-SSX2 in committed myogenic progenitor 
cells results in tumor formation in mice suggesting that the cell-of-origin could be 
a more differentiated entity. However, in this model, genomic plasticity was 
essential, as SYT-SSX2 was non-tumorigenic in differentiated muscle cells 
(Haldar et al., 2007). 
 
Epigenetic mechanism of SYT-SSX2 targeting and function 
 
 A major mechanism of recruitment occurs through interactions with PRCs, 
but like other transcriptional regulators, binding of SYT-SSX2 does not 
completely correlate with changes in gene expression. Studies on cellular 
reprogramming as well as on alterations in chromatin structure during 
differentiation indicate that transcription factor binding and/or differential histone 
modification signatures pre-label genes that may undergo changes in expression 
when given the proper stimulus (Koche et al., 2010; Orford et al., 2008). Thus, 
genes that are bound but whose expression is unaltered may be “poised” for 
activation in response to certain signaling events. Indeed, the dependence of the 
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neural phenotype on FGF signaling supports such a scenario. In this model, 
binding by SYT-SSX2 alters the chromatin structure of neural genes into a 
poised state, and signaling downstream of FGFR2 induces the activation of these 
targets. This suggests that transcriptional activity is directed by extracellular 
signaling, and stimulation of other pathways will result in the generation of 
distinct phenotypes. Comprehension of the complete transformative program will 
consider these alternate fates. 
 Latent programs primed by SYT-SSX2 will also have important 
ramifications on disease progression and treatment response. The studies 
described here are concerned with the acute phase of transformation by the 
oncogene and document how targeting of the chimeric protein dictates early 
events. Genes that are involved in tumor maintenance during later stages of 
progression and/or metastasis could also be pre-marked by SYT-SSX2. It may 
then be possible to predict tumor behavior by knowing the identities of those 
genes and determining pathways that induce their activation. 
 
Molecular mechanism of Polycomb derepression 
 
 Because of its interaction with multiple epigenetic regulatory complexes, 
SYT-SSX2 stands as the central node that organizes transcriptional deregulation. 
Transcription factors possess domains that allow them to interact with multiple 
downstream effectors and thus orchestrate transcription (Frietze and Farnham, 
2011). This includes transactivation domains and other protein-protein interaction 
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modules with the capability to bind activators and repressors. Thus, one protein 
through the same domain can elicit distinct effects (Frietze and Farnham, 2011). 
The SNH domain of SYT may perform this function since it can interact with both 
p300 and mSin3a (Eid et al., 2000; Ito et al., 2004). Differential binding might be 
controlled by upstream extracellular cues like the FGF or other signaling 
pathways providing a direct link between the microenvironment and the control of 
Polycomb. In this way, SYT-SSX2 can execute multiple functions with diverse 
effects at a target gene.  
 Studying the molecular function of SYT-SSX2 will also illuminate the 
sequential recruitment of factors necessary to counteract Polycomb-mediated 
silencing. Understanding this process has considerable implications for normal 
cellular reprogramming (e.g. conversion of fibroblasts to induced pluripotent stem 
cells). Polycomb complexes are part of a larger epigenetic program that must be 
conformed to the structure of the target cell type in order for reprogramming to be 
complete (Gaspar-Maia et al., 2011). Our study on SYT-SSX2 suggests that 
targeted inhibition of PcG proteins in combination with specific signals can 
produce a distinct cell fate. In elaborating how SYT-SSX2 initiates and controls 
this process, and by identifying how genes within a specific program are 
targeted, it will become clearer how to change the epigenetic structure of one cell 
to that of an alternate lineage. Ultimately, this will improve the efficiency of 
cellular reprogramming. 
 Our data indicate that transformation by SYT-SSX2 occurs through 
improper reprogramming of the nucleus most likely via modulation of the 
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activities of epigenetic regulators with cooperation from signaling pathways. This 
has important implications in the treatment of synovial sarcoma. Although 
epigenetic reprogramming is a slow process, once complete, it is persistent. 
Therefore, even in the absence of the initiating signal (i.e. oncogene expression), 
this abnormal nuclear program remains intact (Abollo-Jiménez et al., 2010; 
Castellanos et al., 2010). Indeed, this is characteristic of normal Polycomb-
mediated gene repression (Schuettengruber et al., 2007; Kerppola, 2009) 
suggesting that treatment of synovial sarcoma could become resistant to SYT-
SSX-specific therapeutics and that the most effective therapies will instead target 




Molecular mechanism of SYT-SSX2 function 
 The extracellular signals that govern differentiation and development are 
well-characterized for many tissues, yet the manner in which these pathways 
regulate Polycomb function is incompletely understood. The data presented in 
this study indicate that SYT-SSX2 activity relies on extracellular signaling, 
specifically the FGF pathway. Contributions from other factors in the 
microenvironment are possible, and future efforts should delineate the 
relationship between signaling pathways and the control of transcription by the 
fusion protein. Although associated with a disease phenotype, the cycle of events 
directed by SYT-SSX2 with input from the FGF pathway likely reflect normal 
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mechanisms. Thus it will be informative for researchers who are interested in the 
transcriptional control of differentiation and development as well as those 
investigating possible therapeutic interventions for SS. 
 
Three-dimensional structure of chromatin 
 Polycomb and SWI/SNF mediate higher-order chromatin configurations. 
Many binding sites in our ChIPSeq analysis occur in intergenic regions, so it will 
be fascinating to determine how SYT-SSX2 affects three-dimensional chromatin 
structure. Chromosome conformation capture experiments will build a more 
complete picture of SYT-SSX2 function. These studies will also demonstrate 
whether SYT-SSX2 modulates long-range transcriptional regulation. As a 
preliminary finding, our ChIPSeq analysis revealed the association of SYT-SSX2 
within a region of the H19-Igf2 locus between the 2 genes that drives expression 
of Igf2 in mesodermal tissues (Drewell et al., 2002). As a whole, these 
investigations will yield valuable information concerning the mechanism by which 
chromatin architecture controls transcription. 
 
Therapy and cellular reprogramming 
 The development of effective therapeutics in the treatment of SS will 
require a deep understanding of the tumorigenic program initiated by SYT-SSX2, 
and it will be necessary to establish how this predisposes the cell to respond to 
therapeutic interventions. Additional studies should focus on how the SYT-SSX2 
program is maintained, whether it can be reversed, and the nature of changes in 
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gene expression and fusion protein targeting following various stimuli. Overall, 
these studies will advance our knowledge of how cellular identity is controlled 
and how the pathways that govern differentiation and plasticity may be exploited 
in cancer. This will lead to the generation of new therapeutics with increased 







In vitro phosphorylation 
Bacterially purified Ring1b, Bmi1, or Ring1b-Bmi1 complex was incubated with 
25 µL pOZ- or SYT-SSX2-expressing cell nuclear extract in kinase assay buffer 
(20 mM Tris pH 8.0, 150 mM NaCl, 2 mM DTT, 20 mM MgCl2, 40 µM ATP [plus 5 
µCi -32P-ATP for hot kinase assay]) with protease and phosphatase inhibitors at 
30˚C for 30 minutes. Reactions were stopped by the addition of 2x sample buffer.  
 
In vitro acetylation 
Acetylation assays were performed as previously described (Gu and Roeder, 
1997) with some modification. Bacterially purified Ring1b (2.5 µg), Bmi1 (2.5 µg), 
or Ring1b-Bmi1 complex (2.5 µg each monomer) were incubated in assay buffer 
(50 mM HEPES pH 7.9, 10% glycerol, 1 mM DTT, 1 mM PMSF, 10 mM sodium 
butyrate, 1 µL 14C-acetyl CoA [60 mCi/mmol]) with 100 ng of recombinant human 
p300 catalytic domain (Enzo Life Sciences, Plymouth Meeting, PA) and 2 µg 
HeLa nucleosomes for 1 hour at 30˚C. Reactions were stopped by the addition of 
2x sample buffer. Samples were separated using SDS-PAGE, gels were 














Appendix B Figure B1. SYT-SSX2 inhibits myogenesis in C2C12 myoblasts. 
A) Myogenic profile of C2C12. Western blot shows expression of myogenic markers in the 
myoblasts lysates, detected by rabbit anti-MyoD, MEF2, and Myf5 (Santa Cruz). Differentiation of 
these C2C12 cells was restricted to the muscle lineage. B) Myogenic differentiation of C2C12 
cells. Forty-eight hours post-infection, C2C12 cells expressing either vector control (left panel) or 
SYT-SSX2 (right panel) were stimulated with myogenic differentiation medium (DMEM 
supplemented with 5% horse serum) for 7 days.  Brightfield images were captured at 10x 



















































RARG                                  1.6                                   
 
 
GAPDH                                 1.05 
TNNT1                                 19.3 
PDGFRA                                 38.4 
DKK3                                  6.6 
JMJ2b                                  7.2 
MYOG                                  11.7 
V/X 
   V         X 
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B 
Appendix B Figure B2. Genes downregulated by SYT-SSX2 and their representation 
in the ChIPSeq analysis. 
A) RT-PCR analysis confirmed decreased expression of 6 out of 9 genes selected from 
the C2C12 microarray. They represent mediators of diverse cellular pathways, ranging 
from nuclear receptors (RARG) and PDGF signaling (PDGFRA), to Wnt inhibition (DKK3), 
chromatin modification (JMJ2b), and muscle differentiation (MYOG, TNNT1). GAPDH 
served as cDNA input control. V/X represents the ratio of gene expression signal in vector 
control cells (V) over SYT-SSX2 (X) expressants. Signal intensities were measured with 

























Adipogenesis: Oil Red-O 
Osteogenesis: Alkaline Phosphatase 
Osteogenesis: Alizarin Red 
         Unstimulated                  Stimulated for 3 weeks 
 
Appendix B Figure B3. Adipogenesis and osteogenesis in human hMSCs. Human bone 
marrow stem cells were acquired from Dr Prockop‟s laboratory and purified and tested for 
multipotentiality according to established protocols (Colter et al., 2001; Sekiya et al., 2002). Oil 
Red-O stains lipid droplets in differentiated adipocytes. Alkaline phosphatase is a marker for 








Appendix B Table B1. Commonly upregulated genes between SYT-SSX2-expressing myoblasts and human 
synovial sarcoma tumors. 
Developmental Pathway Mediators 
Gene 
Symbol 
Gene Name Accession Gene 
Symbol 
Gene Name Accession 
FGF18 fibroblast growth factor 18 NM_003862 FGFR2 fibroblast growth factor 
receptor 2 
NM_000141 
FGFR3 fibroblast growth factor 
receptor 3 
NM_000142 GLI2 GLI-Kruppel family 
member GLI2 
NM_005270 
DLL1 delta-like 1 NM_005618 APCDD
1 
adenomatosis polyposis 
coli down-regulated 1 
NM_153000 




TLE4 transducin-like enhancer of 
split 4  
NM_007005 
MEST mesoderm specific 
transcript homolog 
NM_002402 PTH1R parathyroid hormone 1 
receptor 
NM_000316 
Developmental Transcription Factors 
CREB5 cAMP responsive element 
binding protein 5 
NM_00101166
6 
DLX5 distal-less homeobox 5 NM_005221 
ETV4 ets variant gene 4  NM_00107967
5 
FOXD1 forkhead box D1 NM_004472 
HOXB5 homeobox B5 NM_002147 ID2 inhibitor of DNA binding 2 NM_002166 
ID4 inhibitor of DNA binding 4 NM_001546 KLF4 Kruppel-like factor 4 (gut) NM_004235 
SOX9 SRY (sex determining 
region Y)-box 9 
NM_000346 ZBTB10 zinc finger and BTB 
domain containing 10 
NM_00110553
9 
Signaling and Cell Cycle 
AKAP12 A kinase (PRKA) anchor 
protein (gravin) 12 
NM_005100 CCND1 cyclin D1 NM_053056 
CCND2 cyclin D2 NM_001759 CDKN1
C 
cyclin-dependent kinase 
inhibitor 1C (p57, Kip2) 
NM_000076 
IGF2 insulin-like growth factor 2 NM_000612 KCNA1 potassium voltage-gated 
channel, shaker-related 
subfamily, member 1 
NM_000217 
KCNK1 potassium channel, 
subfamily K, member 1 
NM_002245 LGR5 leucine-rich repeat-
containing G protein-
coupled receptor 5 
NM_003667 
LRP8 low density lipoprotein 
receptor-related protein 8 
NM_00101805
4 
MYC v-myc myelocytomato-sis 




protein phosphatase 2, 
regulatory subunit B, 
gamma isoform 
NM_020416 PRKCZ protein kinase C, zeta NM_00103358
1 









TBKBP1 TBK1 binding protein 1 NM_014726 TOM1L1 target of myb1-like 1 NM_005486 
Neural Development and Function 
CBLN1 cerebellin 1 precursor NM_004352 CRHR1 corticotropin releasing 
hormone receptor 1 
NM_00114514
6 
CRMP1 collapsin response 
mediator protein 1 
NM_00101480
9 
DPYSL5 dihydropyrimidin-ase-like 5 NM_020134 
ECEL1 endothelin converting 
enzyme-like 1 
NM_004826 EPHA4 EPH receptor A4 NM_004438 
EPHB1 EPH receptor B1 NM_004441 FAAH fatty acid amide hydrolase NM_001441 













MN1 meningioma 1 NM_002430 
NGFR nerve growth factor 
receptor  
NM_002507 NPTX1 neuronal pentraxin I NM_002522 
NRGN neurogranin  NM_00112618
1 
OLFM1 olfactomedin 1 NM_006334 
OLIG2 oligodendrocyte lineage 
transcription factor 2 
NM_005806 RDH10 retinol dehydrogenase 10 
(all-trans) 
NM_172037 
RGS16 regulator of G-protein 
signalling 16 
NM_002928 RTN4R reticulon 4 receptor NM_023004 
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SLC6A1 solute carrier family 6, 
member 1 
NM_003042 SLIT3 slit homolog 3 NM_003062 
SULT4A
1 
sulfotransferase family 4A, 
member 1 
NM_014351 TH tyrosine hydroxylase NM_000360 
ZIC2 Zic family member 2 NM_007129    
Other 
CPXM2 carboxypeptidase X (M14 
family), member 2 
NM_198148 DUS4L dihydrouridine synthase 4-
like  
NM_181581 
ETV5 ets variant gene 5  NM_004454 FLRT3 fibronectin leucine rich 
transmembrane protein 3 
NM_013281 











NM_006041 KRT17 keratin 17 NM_000422 
KRT19 keratin 19 NM_002276 MLLT4 myeloid/lymphoid or 
mixed-lineage leukemia; 
translocated to, 4 
NM_00104000
0 
NR4A1 nuclear receptor subfamily 
4, group A, member 1 
NM_002135 ODC1 ornithine decarboxylase 1 NM_002539 
PDZD2 PDZ domain containing 2 NM_178140 PEG10 paternally expressed 10 NM_00104015
2 
PVRL1 poliovirus receptor-related 
1 

















WDR43 WD repeat domain 43 NM_015131 
WFDC2 WAP four-disulfide core 
domain 2 
NM_006103    
 
 
Appendix B Table B2. Developmental pathway mediators and developmental transcription factors upregulated by 
SYT-SSX2 in myoblasts. 




Gene Name Accession Gene 
Symbol 
Gene Name Accession 
Wnt 
Apcdd1 adenomatosis polyposis 
coli down-regulated 1 
NM_133237  Axin2* Axin 2 NM_015732  
Dact1 dapper homolog 1, 
antagonist of beta-catenin 
NM_021532 Fzd3* frizzled homolog 3 NM_021458  
 
Tcf7 transcription factor 7, T-cell 
specific 




Tle4 transducin-like enhancer of 
split 4 
NM_011600  Wnt11 wingless-related MMTV 
integration site 11 
NM_009519  
Wnt4 wingless-related MMTV 
integration site 4 
NM_009523  Wnt7a* wingless-related MMTV 
integration site 7A 
NM_009527  
Wnt7b wingless-related MMTV 
integration site 7B 
NM_009528     
Notch 
Dll1 delta-like 1 NM_007865  Hes1 hairy and enhancer of split 
1 
NM_008235  
Nrarp Notch-regulated ankyrin 
repeat protein 
NM_025980     
TGF/BMP 
Gdf6 growth differentiation factor 
6 
NM_013526 Nog noggin NM_008711  
Tgfbr1 transforming growth factor, 
beta receptor I 
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Shh 




Ptch1 patched homolog 1 NM_008957  
Shh* sonic hedgehog NM_009170     
FGF 
Fgf18 fibroblast growth factor 18 NM_008005  Fgf3* fibroblast growth factor 3 NM_008007  
Fgf7 fibroblast growth factor 7 NM_008008  Fgf9 fibroblast growth factor 9 NM_013518  
Fgfr2* fibroblast growth factor 
receptor 2 
NM_010207  Fgfr3 fibroblast growth factor 
receptor 3 
NM_008010  
Shisa2 shisa homolog 2 NM_145463     
Developmental Transcription Factors 
Gene 
Symbol 
Gene Name Accession Gene 
Symbol 
Gene Name Accession 
Dlx3 distal-less homeobox 3 NM_010055 Dlx5* distal-less homeobox 5 NM_010056 
Dmrta1 doubesex and mab-3 
related transcription factor 
like family A1 
NM_175647 Ehf ets homologous factor NM_007914 
Esrrb estrogen related receptor, 
beta 
NM_011934 Foxc2 forkhead box C2 NM_013519 
Foxf1a* forkhead box F1a NM_010426 Grhl3 grainyhead-like 3 NM_00101375
6 
Hoxb13* homeo box B13 NM_008267  Hoxb5 homeo box B5 NM_008268  
Hoxb6 homeo box B6 NM_008269 Hoxb8 homeo box B8 NM_010461  
Hoxb9 homeo box B9 NM_008270 Id2 inhibitor of DNA binding 2 NM_010496 
Id4 inhibitor of DNA binding 4 NM_031166 Klf4 Kruppel-like factor 4 (gut) NM_010637 
Mafb* v-maf musculoaponeurotic 
fibrosarcoma oncogene 
family, protein B 
NM_010658 Msx1* homeobox, msh-like 1 NM_010835 
Nfil3 nuclear factor, interleukin 
3, regulated 
NM_017373 Nr4a3 nuclear receptor subfamily 
4, group A, member 3 
NM_015743 
Pax9 paired box gene 9 NM_011041 Sox9 SRY-box containing gene 
9 
NM_011448 
Spib* Spi-B transcription factor NM_019866 Tbx20 T-box 20 NM_194263 









Appendix B Table B3. Genes involved in neural development and function upregulated by SYT-SSX2 in 
myoblasts. 
Development and Differentiation 
Gene 
Symbol 
Gene Name Accession Gene 
Symbol 
Gene Name  Accession 
Barx2 BarH-like homeobox NM_013800 Bhlhb4 basic helix-loop-helix 
family, class B4 
NM_080641  
Bsnd Bartter syndrome, infantile, 
with sensorineural 
deafness 




Dtx1 deltex 1 homolog NM_008052  Fezf2 Fez family zinc finger 2 NM_080433  




L1cam L1 cell adhesion molecule NM_008478  Lhx1 LIM homeobox protein 1 NM_008498 
Lhx2 LIM homeobox protein 2 NM_010710  Lhx5 LIM homeobox protein 5 NM_008499 
Nog noggin NM_008711  Olig1 oligodendrocyte 
transcription factor 1 
NM_016968  
Olig2 oligodendrocyte 
transcription factor 2 
NM_016967  Pou3f1 POU domain, class 3, 









Ret ret proto-oncogene NM_00108078
0  
Rorb RAR-related orphan 
receptor beta 
NM_146095  




translocase of inner 
mitochondrial membrane 8 
homolog a1  
NM_013898  
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Zcchc12 zinc finger, CCHC domain 
containing 12 
NM_028325  Zic2 Zinc finger protein of the 
cerebellum 2 
NM_009574  
Patterning and Axon Guidance 
Crmp1 collapsin response 
mediator protein 1 
NM_007765  Dpysl5 Dihydropyrimidin-ase-like 5 NM_023047  
Efna3 ephrin A3 NM_010108  Efnb1 ephrin B1 NM_010110  
Epha4 Eph receptor A4 NM_007936 Epha8 Eph receptor A8 NM_007939  
Ephb1 Eph receptor B1 NM_173447  Gpr56 G protein-coupled receptor 
56 
NM_018882  
Ntng2 netrin G2 NM_133501  Rtn4r reticulon 4 receptor NM_022982  
Rtn4rl1 reticulon 4 receptor-like 1 NM_177708  Sema6b semaphorin 6B NM_013662  
Sema7a semaphorin 7A NM_011352  Slit3 slit homolog 3  NM_011412  
Srgap1 SLIT-ROBO Rho GTPase 
activating protein 1 
NM_00108103
7 
Tspan7 tetraspanin 7 NM_019634  
Unc5a unc-5 homolog A  NM_153131     
Neurotransmitter Signaling and Metabolism 
Abat 4-aminobutyrate 
aminotransferase 
NM_172961  Adra2c adrenergic receptor NM_007418  
Chrna4 cholinergic receptor NM_015730  Grik3 glutamate receptor NM_00108109
7  
Grm4 glutamate receptor NM_00101338
5  
Kcnip3 Kv channel interacting 
protein 3, calsenilin 
NM_019789  
Nptx1 neuronal pentraxin 1 NM_008730  Slc18a3 solute carrier family 18, 
member 3 
NM_021712  
Slc6a1 solute carrier family 6, 
member 1 
NM_178703  Slc6a11 solute carrier family 6, 
member 11 
NM_172890  
Slc6a12 solute carrier family 6, 
member 12 
NM_133661  Slc6a13 solute carrier family 6, 
member 13 
NM_144512  
Syngr3 synaptogyrin 3 NM_011522  Th tyrosine hydroxylase NM_009377  
Neuropeptide, Lipid, and Hormone Signaling 
Cck cholecystokinin NM_031161  Chga chromogranin A NM_007693  
Crhr1 corticotropin releasing 
hormone receptor 1 
NM_007762  Faah fatty acid amide hydrolase NM_010173  
Gal galanin NM_010253  Gpr50 G protein-coupled receptor 
50 
NM_010340  
Mgll monoglyceride lipase NM_011844  Npy neuropeptide Y NM_023456  
Nrgn neurogranin NM_022029  Nts neurotensin NM_024435  
Ntsr1 neurotensin receptor 1 NM_018766  Nxph4 neurexophilin 4 NM_183297  
Pdyn prodynorphin NM_018863  Pnoc prepronociceptin NM_010932  
Sst somatostatin NM_009215     
Adhesion, Growth, and Survival 
Amigo2 adhesion molecule with Ig 
like domain 2 
NM_178114  Bai1 brain-specific angiogenesis 
inhibitor 1 
NM_174991  
Bai2 brain-specific angiogenesis 
inhibitor 2 
NM_173071  Cadm1 cell adhesion molecule 1 NM_207676  
Cdh22 cadherin 22 NM_174988  Cdh23 cadherin 23 (otocadherin) NM_023370 
Cntfr ciliary neurotrophic factor 
receptor 
NM_016673  Gap43 growth associated protein 
43 
NM_008083  
Gdnf glial cell derived 
neurotrophic factor 
NM_010275  Gfra1 glial cell derived 
neurotrophic factor family 
receptor alpha 1 
NM_010279  
Gjb2 gap junction membrane 
channel protein beta 2 
NM_008125  Gjb4 gap junction protein, beta 4 NM_008127  




cell adhesion molecule 
NM_176930     
Other 
Adcy5 adenylate cyclase 5 NM_00101276
5 
Agrn agrin NM_021604  
Arc activity regulated 
cytoskeletal-associated 
protein 
NM_018790  Asrgl1 asparaginase like 1 NM_025610  
Brp16 brain protein 16 NM_021555  
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Cacna1h calcium channel, voltage-
dependent, T type, alpha 
1H subunit 
NM_021415  Cacng5 calcium channel, voltage-






dependent protein kinase II 
inhibitor 1 
NM_025451 Camk4 calcium/calmodu-lin-




Cbln1 cerebellin 1 precursor 
protein 
NM_019626  Cd40 CD40 antigen NM_170701  
Churc1 churchill domain containing 
1 
NM_206534  Ckb creatine kinase, brain NM_021273  
Clu clusterin NM_013492  Cntn2 contactin 2 NM_177129  
Cpeb1 cytoplasmic 
polyadenylation element 
binding protein 1 
NM_007755  Cpne6 copine VI NM_009947  




DNA segment, Chr 11, 
Brigham & Women's 
Genetics 0517 expressed 
NM_00103916
7  
Dlgap4 discs, large homolog-
associated protein 4 
NM_146128  Dok7 docking protein 7 NM_172708  
Ecel1 endothelin converting 
enzyme-like 1 
NM_021306 Fjx1 four jointed box 1 NM_010218  
Flrt1 fibronectin leucine rich 
transmembrane protein 1 




Hpcal4 hippocalcin-like 4 NM_174998  Kcna1 potassium voltage-gated 
channel, shaker-related, 
subfamily, member 1 
NM_010595  
Kcnc4 potassium voltage gated 
channel, Shaw-related 
subfamily, member 4 
NM_145922  Kcnj14 potassium inwardly-
rectifying channel, 
subfamily J, member 14 
NM_145963  
Kcnma1 potassium large 
conductance calcium-
activated channel, 
subfamily M, alpha 
member 1 
NM_010610  Kcnn3 potassium intermediate/ 
small conduc-tance 
calcium-activated channel, 
subfamily N, member 3 
NM_080466  
Kif1a kinesin family member 1A NM_008440 Lgi1 leucine-rich repeat LGI 
family, member 1 
NM_020278  
Lrrc8d leucine rich repeat 
containing 8D 











Mn1 meningioma 1 NM_00108123
5 
Msi1 Musashi homolog 1 NM_008629  
Mtap1b microtubule-associated 
protein 1B 
NM_008634  Myo7a myosin VIIA NM_008663  
Ndrg1 N-myc downstream 
regulated gene 1 
NM_008681  Nefh neurofilament, heavy 
polypeptide 
NM_010904  
Nefm neurofilament, medium 
polypeptide 
NM_008691  Ninj1 ninjurin 1 NM_013610  
Nos1ap nitric oxide synthase 1 
(neuronal) adaptor protein 
NM_027528  Oc90 otoconin 90 NM_010953  
Olfm1 olfactomedin 1 NM_019498  Olfr1029 olfactory receptor 1029 NM_00101185
2  
Olfr171 olfactory receptor 171 NM_146958  Olfr172 olfactory receptor 172 NM_147001  
Olfr767 olfactory receptor 767 NM_146318  Pcp4 Purkinje cell protein 4 NM_008791  




Plxna4 plexin A4 NM_175750  




Rcan1 regulator of calcineurin 1 NM_00108154
9  




Reep6 receptor accessory protein 
6 
NM_139292  Rgnef Rho-guanine nucleotide 
exchange factor 
NM_012026  
Rgs16 regulator of G-protein 
signaling 16 
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Rnd1 Rho family GTPase 1 NM_172612  Rundc3a RUN domain containing 3A NM_016759  
Serpina3
n 
serine (or cysteine) 
peptidase inhibitor, clade 
A, member 3N 
NM_009252  Sez6l seizure related 6 homolog 
like 
NM_019982  




Slc17a7 solute carrier family 17, 
member 7 
NM_182993  
Slc1a1 solute carrier family 1, 
member 1  
NM_009199  Spns2 spinster homolog 2 BC025823  




Syt12 synaptotagmin XII NM_134164  




Tnr tenascin R NM_022312 Uchl1 ubiquitin carboxy-terminal 
hydrolase L1 
NM_011670  
Znrf2 zinc and ring finger 2 NM_199143     
 
 




Gene Name Accession Gene 
Symbol 
Gene Name  Accession 
Acta1 actin, alpha 1, skeletal 
muscle 
NM_009606  Acta2 actin, alpha 2, smooth 
muscle, aorta 
NM_007392  
Actc1 actin, alpha, cardiac NM_009608  Actn3 actinin alpha 3 NM_013456  
Atp2a1 ATPase, Ca++ 
transporting, cardiac 
muscle, fast twitch 1 
NM_007504  Bgn biglycan NM_007542  
Bves blood vessel epicardial 
substance 
NM_024285  Car3 carbonic anhydrase 3 NM_007606  
Cdon cell adhesion molecule-
related/down-regulated by 
oncogenes 
NM_021339  Chrna1 cholinergic receptor, 
nicotinic, alpha polypeptide 
1 (muscle) 
NM_007389  
Chrnd cholinergic receptor, 
nicotinic, delta polypeptide 




Col6a1 procollagen, type VI, alpha 
1 
NM_009933  Col6a2 procollagen, type VI, alpha 
2 
NM_146007  
Col6a3 procollagen, type VI, alpha 
3, mRNA 
BC057903  Des desmin NM_010043  
Dmpk dystrophia myotonica-
protein kinase 
NM_032418  Dtna dystrobrevin alpha NM_207650  
Ehd2 EH-domain containing 2 NM_153068  Eno3 enolase 3, beta muscle NM_007933  




Itga7 integrin alpha 7 NM_008398  Ldb3 LIM domain binding 3 NM_00103907
4  




AJ277212  Myf5 myogenic factor 5 NM_008656  
Myl1 myosin, light polypeptide 1 NM_021285  Myl4 myosin, light polypeptide 4 NM_010858  
Myl9 myosin, light polypeptide 9, 
regulatory 
BC055439  Mylk myosin, light polypeptide 
kinase 
NM_139300  
Mylpf myosin light chain, 
phosphorylatable, fast 
skeletal muscle 
NM_016754  Myod1 myogenic differentiation 1 NM_010866  
Myog myogenin NM_031189  P2rx6 purinergic receptor P2X, 
ligand-gated ion channel, 6 
NM_011028  
Pdlim3 PDZ and LIM domain 3 NM_016798  Popdc3 popeye domain containing 
3 
NM_024286  
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Sgcb sarcoglycan, beta 
(dystrophin-associated 
glycoprotein) 









Six4 sine oculis-related 
homeobox 4 homolog 
(Drosophila) 
NM_011382  
Speg SPEG complex locus NM_007463  Sspn sarcospan NM_010656  
Sync syncoilin NM_023485  Tnnc1 troponin C, cardiac/slow 
skeletal 
NM_009393  
Tnni1 troponin I, skeletal, slow 1 NM_021467  Tnnt1 troponin T1, skeletal, slow NM_011618  
Tnnt3 troponin T3, skeletal, fast NM_011620  Ttn titin NM_011652  
Unc93b1 unc-93 homolog B1 (C. 
elegans) 
NM_019449  Boc biregional cell adhesion 
molecule-related/down-
regulated by oncogenes 








Gene Name Accession Gene 
Symbol 
Gene Name Accession 
ALPL alkaline phosphatase NM_000478 BMP2 bone morphogenetic 
protein 2 
NM_001200 
BMP6 bone morphogenetic 
protein 6 
NM_001718 COMP cartilage oligomeric matrix 
protein 
NM_000095 
CRTAC1 cartilage acidic protein  NM_018058 FGFR3 fibroblast growth factor 
receptor 3 
NM_000142 
HOXD1 homeobox D1 NM_024501 HOXD10 homeobox D10 NM_002148 
IGSF10 immunoglobulin 
superfamily, member 10 
NM_178822 LIFR leukemia inhibitory factor 
receptor  
NM_002310 
MGP matrix Gla protein NM_000900 OSR2 odd-skipped related 2 NM_053001 
ROR2 receptor tyrosine kinase –
like 2 




Appendix B Table B6. Differentially regulated genes in C2C12 myoblasts and hMSCs expressing SYT-SSX2. 
Underlined genes are downregulated in both C2C12 myoblasts and hMSCs expressing SYT-SSX2.  
Gene 
Symbol 
Gene Name Accession Gene 
Symbol 
Gene Name Accession 
Adhesion, Migration, and ECM 
Arhgap2
0 
Rho GTPase activating 
protein 20 
NM_175535  Ceacam1 carcinoembryonic 
antigen-related cell 
adhesion molecule 1 
NM_011926  
Cldn1 claudin 1 NM_016674  Col4a1 collagen, type IV, alpha 
I 
NM_009931  
Crispld2 cysteine-rich secretory 
protein LCCL domain 
containing 2 





Icam1 intercellular adhesion 
molecule 1 




Itga9 integrin alpha 9 NM_133721  Krt17 keratin 17 NM_010663  
Krt6a keratin 6a NM_008476  Mmp10 matrix 
metallopeptidase 10 
NM_019471  
Rhou ras homolog gene 
family, member U 
NM_133955  Scube1 signal peptide, CUB 
domain, EGF-like 1 
NM_022723  
Tnxb tenascin XB NM_031176  Arhgap1
8 
Rho GTPase activating 
protein 18 
NM_176837  
Ccbe1 collagen and calcium 
binding EGF domains 1 
NM_178793  Ccdc80 coiled-coil domain 
containing 80 
NM_026439  
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Fap fibroblast activation 
protein 




Itgb8 integrin beta 8 NM_177290  Loxl1 lysyl oxidase-like 1 NM_010729  







Nid1 nidogen 1 NM_010917  Pcdh18 protocadherin 18 NM_130448  
Postn periostin, osteoblast 
specific factor 








NM_133237 Axin2 Axin 2 NM_015732  
Dact1 dapper homolog 1, 
antagonist of beta-
catenin 
NM_021532 Fzd3 frizzled homolog 3 NM_021458  
 
Tle3 transducin-like 
enhancer of split 3 
NM_001083927  Wnt11 wingless-related MMTV 
integration site 11 
NM_009519  
Wnt4 wingless-related MMTV 
integration site 4 
NM_009523  Wnt7b wingless-related MMTV 
integration site 7B 
NM_009528  
Fzd2 frizzled homolog 2 NM_020510     
Developmental Pathway Mediators: Notch 




ankyrin repeat protein 
NM_025980     
Developmental Pathway Mediators: TGF/BMP 
Gdf6 growth differentiation 
factor 6 
NM_013526 Smad6 MAD homolog 6 NM_008542  
Tgfbr2 transforming growth 
factor, beta receptor II 
NM_009371    
Developmental Pathway Mediators: Shh 
Ptch1 patched homolog 1 NM_008957  Shh sonic hedgehog NM_009170  
Developmental Pathway Mediators: FGF 
Fgf9 fibroblast growth factor 
9 
NM_013518  Fgfr2 fibroblast growth factor 
receptor 2 
NM_010207  
Fgfr3 fibroblast growth factor 
receptor 3 
NM_008010  Shisa2 shisa homolog 2 NM_145463  
Developmental Pathway Mediators: PDGF 
Pdgfc platelet-derived growth 
factor, C 
NM_019971  Pdgfra platelet-derived growth 
factor receptor, alpha 
polypeptide 
NM_011058  
Developmental Pathway Mediators: Other 
Adssl1 adenylosuccinate 
synthetase like 1 
NM_007421  Alpl alkaline phosphatase NM_007431 
Calcr calcitonin receptor NM_007588 Flt4 FMS-like tyrosine 
kinase 4 
NM_008029  





subfamily G, member 1 
NM_001081134  Kdr kinase insert domain 
protein receptor 
NM_010612  
Laptm lysosomal protein 
transmembrane 5 
NM_010686  Sik1 salt inducible kinase 1 NM_010831  
Angpt1 angiopoietin 1 NM_009640  Aspn asporin NM_025711  
Emilin 1 elastin microfibril 
interfacer 1 
NM_133918  Mylk myosin, light 
polypeptide kinase 
NM_139300  
Popdc3 popeye domain 
containing 3 
NM_024286  Sgcd sarcoglycan, delta NM_011891  
Sync syncoilin NM_023485     
Developmental Transcription Factors 
Creb5 cAMP responsive 
element binding protein 
5 
NM_172728 Dlx3 distal-less homeobox 3 NM_010055 
Etv4 ets variant 4 NM_008815 Grhl3 grainyhead-like 3 NM_001013756 
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Hoxb6 homeo box B6 NM_008269 Hoxb9 homeo box B9 NM_008270 
Lbh limb bud and heart 
development 
NM_029999 Mafb v-maf 
musculoaponeurotic 
fibrosarcoma oncogene 
family, protein B 
NM_010658 
Nr4a3 nuclear receptor 
subfamily 4, group A, 
member 3 
NM_015743 Tbx20 T-box 20 NM_194263 
Bnc2 basonuclin 2 NM_172870     
Metabolism 
Ak4 adenylate kinase 4 NM_009647  Alox15 arachidonate 15-
lipoxygenase 
NM_009660  
Atp1a3 ATPase, Na+/K+ 
transporting, alpha 3 
polypeptide 




helicase DNA binding 
protein 7 
NM_001081417  Chi3l1 chitinase 3-like 1 NM_007695  
Cnih2 cornichon homolog 2 NM_009920  Cyp26b1 cytochrome P450, 
family 26, subfamily b, 
polypeptide 1 
NM_175475  
Egr2 early growth response 
2 
NM_010118  Elovl7 ELOVL family member 
7, elongation of long 
chain fatty acids 
NM_029001  
Fgg fibrinogen gamma 
chain 




Irf4 interferon regulatory 
factor 4 
NM_013674  Mgat4a mannoside 
acetylglucosaminyltran
sferase 4, isoenzyme A 
NM_173870  
Rnf125 ring finger protein 125 NM_026301  Slc38a3 solute carrier family 38, 
member 3 
NM_023805  
Strbp spermatid perinuclear 
RNA binding protein 






NM_170778  Glrx glutaredoxin NM_053108  
Mgst1 microsomal glutathione 
S-transferase 1 

















NM_011198  Slc44a1 solute carrier family 44, 
member 1 
AK141895  
Slc8a1 solute carrier family 8 
(sodium/calcium 
exchanger), member 1 
NM_011406  Sqrdl sulfide quinone 
reductase-like 
NM_021507  
Ssbp2 single-stranded DNA 
binding protein 2 
NM_024272     
Neural Development and Function: Development and Differentiation 
Dtx1 deltex 1 homolog NM_008052  L1cam L1 cell adhesion 
molecule 
NM_008478  
Lhx1 LIM homeobox protein 
1 
NM_008498 Lhx2 LIM homeobox protein 
2 
NM_010710  
Lhx5 LIM homeobox protein 
5 
NM_008499 Nog noggin NM_008711  
Prox1 prospero-related 
homeobox 1 




Ret ret proto-oncogene NM_001080780  Rorb RAR-related orphan 
receptor beta 
NM_146095  
Zcchc12 zinc finger, CCHC 
domain containing 12 
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Neural Development and Function: Patterning and Axon Guidance 
Crmp1 collapsin response 
mediator protein 1 
NM_007765  Dpysl5 Dihydropyrimidin-ase-
like 5 
NM_023047  
Efna3 ephrin A3 NM_010108  Efnb1 ephrin B1 NM_010110  
Epha4 Eph receptor A4 NM_007936 Ephb1 Eph receptor B1 NM_173447  
Gpr56 G protein-coupled 
receptor 56 
NM_018882  Ntng2 netrin G2 NM_133501  
Sema6b semaphorin 6B NM_013662  Slit3 slit homolog 3  NM_011412  
Tspan7 tetraspanin 7 NM_019634  Unc5a unc-5 homolog A  NM_153131  
Sema3a sema domain, 
immunoglobulin 
domain (Ig), short basic 
domain, secreted, 
(semaphorin) 3A 
NM_009152     
Neural Development and Function: Neurotransmitter Signaling and Metabolism 
Abat 4-aminobutyrate 
aminotransferase 
NM_172961  Chrna4 cholinergic receptor NM_015730  
Grik3 glutamate receptor NM_001081097  Grm4 glutamate receptor NM_001013385  
Slc18a3 solute carrier family 18, 
member 3 
NM_021712  Slc6a1 solute carrier family 6, 
member 1 
NM_178703  
Syngr3 synaptogyrin 3 NM_011522  Glrb glycine receptor beta NM_010298  
 
Neural Development and Function: Neuropeptide, Lipid, and Hormone Signaling 
Chga chromogranin A NM_007693  Crhr1 corticotropin releasing 
hormone receptor 1 
NM_007762  
Gal galanin NM_010253  Gpr50 G protein-coupled 
receptor 50 
NM_010340  
Npy neuropeptide Y NM_023456  Nts neurotensin NM_024435  
Ntsr1 neurotensin receptor 1 NM_018766  Nxph4 neurexophilin 4 NM_183297  
Pnoc prepronociceptin NM_010932  Sst somatostatin NM_009215  
Mrgprf MAS-related GPR, 
member F 
NM_145379     








Cadm1 cell adhesion molecule 
1 
NM_207676  Cdh23 cadherin 23 
(otocadherin) 
NM_023370 
Cntfr ciliary neurotrophic 
factor receptor 
NM_016673  Gfra1 glial cell derived 
neurotrophic factor 
family receptor alpha 1 
NM_010279  
Gjb2 gap junction membrane 
channel protein beta 2 




related cell adhesion 
molecule 
NM_176930  Drp2 dystrophin related 
protein 2 
NM_010078  
Neural Development and Function: Other 
Adcy5 adenylate cyclase 5 NM_001012765 Cacna1h calcium channel, 
voltage-dependent, T 




kinase II inhibitor 1 
NM_025451 Cbln1 cerebellin 1 precursor 
protein 
NM_019626  
Ckb creatine kinase, brain NM_021273  Clu clusterin NM_013492  
Crlf1 cytokine receptor-like 
factor 1 
NM_018827  Ecel1 endothelin converting 
enzyme-like 1 
NM_021306 
Flrt1 fibronectin leucine rich 
transmembrane protein 
1 
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Kif1a kinesin family member 
1A 
NM_008440 Mapt microtubule-associated 
protein tau 
NM_001038609  
Nefh neurofilament, heavy 
polypeptide 
NM_010904  Nefm neurofilament, medium 
polypeptide 
NM_008691  
Olfm1 olfactomedin 1 NM_019498  Pde2a phosphodiester-ase 
2A, cGMP-stimulated 
NM_001008548 




Reep6 receptor accessory 
protein 6 
NM_139292  
Rgs16 regulator of G-protein 
signaling 16 
NM_011267 Sez6l seizure related 6 
homolog like 
NM_019982  
Slc16a6 solute carrier family 16, 
member 6 
NM_001029842  Slc17a7 solute carrier family 17, 
member 7 
NM_182993  
Spns2 spinster homolog 2 BC025823  Stra6 stimulated by retinoic 
acid gene 6 
NM_009291  
 
Tnfrsf21 tumor necrosis factor 
receptor superfamily, 
member 21 




protein, X-linked 2 




Signaling and Cell Cycle 
Atp2b2 ATPase, Ca++ 
transporting, plasma 
membrane 2 
NM_001036684  C3 complement 
component 3 
NM_009778  
Cacna1g calcium channel, 
voltage-dependent, T 







alpha 2/delta subunit 2 
NM_020263  
Ccl2 chemokine (C-C motif) 
ligand 2 
NM_011333  Ccl20 chemokine (C-C motif) 
ligand 20 
NM_016960  
Ccl7 chemokine (C-C motif) 
ligand 7 
NM_013654  Ccnd2 cyclin D2 NM_009829  
Cx3cl1 chemokine (C-X3-C 
motif) ligand 1 
NM_009142  Cxcl1 chemokine (C-X-C 
motif) ligand 1 
NM_008176  
Cxcl14 chemokine (C-X-C 
motif) ligand 14 
NM_019568  Cxcr4 chemokine (C-X-C 
motif) receptor 4 
NM_009911  
Cyfip2 cytoplasmic FMR1 
interacting protein 2 
NM_133769  Dapk1 death associated 
protein kinase 1 
NM_029653  
Errfi1 ERBB receptor 
feedback inhibitor 1 
NM_133753  Gpr120 G-protein coupled 
receptor 120 
NM_181748  
Gucy1a3 guanylate cyclase 1, 
soluble, alpha 3 
NM_021896 Lgr5 leucine rich repeat 
containing G protein 
coupled receptor 5 
NM_010195  
Lrp8 low density lipoprotein 
receptor-related protein 
8, apolipoprotein e 
receptor 




Peg10 paternally expressed 
10 
NM_130877 Peli1 pellino 1 NM_023324  
Ppp2r2c protein phosphatase 2 
(formerly 2A), 
regulatory subunit B 
(PR 52), gamma 
isoform 
NM_172994  Prkch protein kinase C, eta NM_008856  
Ptprn protein tyrosine 
phosphatase, receptor 
type, N 
NM_008985  Pyy peptide YY NM_145435  
Rap1gap Rap1 GTPase-
activating protein 





regulated kinase 1 
NM_011361  Slc9a3 solute carrier family 9 
(sodium/hydrogen 
exchanger), member 3 
NM_001081060  
 
Slco4a1 solute carrier organic 
anion transporter 
family, member 4a1 




component 1, s 
subcomponent 
NM_144938  Cfh complement 
component factor h 
NM_009888  
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Copz2 coatomer protein 
complex, subunit zeta 
2 
NM_019877  Dab2 disabled homolog 2 NM_023118  
Dock5 dedicator of cytokinesis 
5 
NM_177780  Gulp1 GULP, engulfment 
adaptor PTB domain 
containing 1 
NM_027506  
Npr3 natriuretic peptide 
receptor 3 
NM_001039181  Psd3 pleckstrin and Sec7 
domain containing 3 
NM_177698  
Rab27b RAB27b, member RAS 
oncogene family 





NM_016911  Synj2 synaptojanin 2 NM_011523  
Other 
Lonrf3 LON peptidase N-
terminal domain and 
ring finger 3 





1 like 2 
NM_001081337  Slc35f2 solute carrier family 35, 
member F2 
NM_028060  
Tmcc3 transmembrane and 










NM_172583  Tspan18 tetraspanin 18 NM_183180  
Dsel dermatan sulfate 
epimerase-like 
NM_001081316  Gramd1b GRAM domain 
containing 1B 
NM_172768  
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